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Abstract 
 Boron neutron capture therapy (BNCT) is a brachyradiotherapy that exploits the 
large thermal neutron (~0.025eV) cross-section of 10B.  After absorbing a neutron, a 11B 
compound nucleus will spontaneously fission into an alpha particle and a lithium nucleus.  
An average energy of 2.31 MeV is deposited in a volume on the order of one cell 
diameter.  The large masses and high energies of ion products constitute a high linear 
energy transfer (LET) reaction.  High LET reactions cause double stranded 
deoxyribonucleic acid (ds-DNA) breaks that lead to cell death because the breaks cannot 
be accurately repaired.  BNCT has been used in clinical trials to treat the aggressive 
infiltrative brain malignancy, glioblastoma multiforme, and the skin cancer, melanoma.  
The few studies on melanoma seem to be more promising than the trials on glioblastoma.  
The cellular level energy deposition pattern, the microdosimetry, reveals the reason for 
the observed differences. 
 Programs were written modeling cells as ellipsoids arranged in a body centered 
cubic with nuclei that can be spheres or ellipsoids independent of the cell and non-
concentric.  The dose was calculated for various boron concentrations in the interstitium, 
the cell cytoplasm, and the cell nuclei for different geometries.  The results demonstrate 
that cells closely packed receive a larger dose than widely separate cells.  Also, the dose 
increases linearly with boron concentration so that better boron delivery agents will 
improve the efficacy.  Infiltrative glioblastoma cells that are in small clumps or isolated 
receive a smaller dose than melanoma cells that are tightly packed.  The microdosimetric 
model corresponds to clinically observed results.  Also, the model predicts that improved 
boron delivery agents could make glioblastoma a disease that is curable by BNCT. 
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Preface 
 Cancer causes much human suffering as well as economic losses due to lost 
wages and the cost of therapy.  Despite monumental medical efforts, cancer remains 
difficult to cure for many cell types.   Often, treatment regimens cause considerable 
morbidity and occasional mortality.  The treatment regimen often has connected 
morbidities that are significant enough to cause the patient to miss work for some time 
after the completion of the therapy.  The search continues to find a safe, focused, 
efficacious radiotherapy with minimal morbidity.  Boron neutron capture therapy 
(BNCT) has shown promise in clinical trials for potentially achieving these goals for 
some cancers. 
 The essential requirements for successful BNCT are the delivery of an adequate 
beam of thermal neutrons to the tumor and the preferential concentration of a boronated 
compound in the tumor cells.  The requirement for an adequate fluence of thermal 
neutrons to the tumor volume is now met at all clinical treatment centers but the 
preferential concentration of a boronated compound in the tumor, as compared to the 
local normal tissues, has proven to be a more difficult goal to achieve.  Current 
compounds used for BNCT tend to concentrate in the tumor compared to normal tissue in 
a ratio of 3-5:1.  Increasing this ratio should improve the efficacy of BNCT so accurate 
determination of this ratio is imperative.  Unfortunately, the determination of the boron 
concentration in various tissues, especially in vivo, has proved to be a difficult task.  All 
current clinical techniques to determine this ratio have proven to be inadequate.  The 
problem may be solved by fluorinating the BNCT compound, para-boronophenylalanine 
(BPA), with fluorine-18 (a positron emitting radionuclide) and performing positron 
emission tomography (PET).  This allows direct identification of the tissue distribution of 
the 18F-BPA.  The resulting boron distribution map may then be used to modify the 
standard treatment plans.  There are significant differences noted when the in vivo PET 
derived boron concentrations in dosimetry calculations are used; this could affect the 
clinical results. 
 The actual cause of cellular demise immediately following radiation exposure is 
still not entirely known.  Damage to the cell’s nucleus and deoxyribonucleic acid (DNA) 
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can lead to cellular death or premature apoptosis.  This explains the cell death that occurs 
some hours, if not days or months, later, but does not explain the immediate cellular 
destruction that is seen after a substantial radiation exposure.  Microdosimetry attempts to 
understand these phenomena and explain them in terms of fundamental physical 
processes on the cellular level.  By examining the microdosimetry of BNCT, the use of 
this modality for cancer therapy may be enhanced and the possible causes of immediate 
cellular demise may be elucidated. 
 BNCT has been used to treat the most common primary brain malignancy, 
glioblastoma multiforme.  This is an aggressive infiltrative tumor that results in a life 
expectancy of six months without treatment.  The optimal conventional therapy is 
debulking surgery, followed by photon beam radiation therapy, and then chemotherapy 
with carmustine (BCNU). This protocol increases the patient’s mean life expectancies to 
12.5 months.  Clinical trials using a single treatment of BNCT following debulking 
surgery have yielded median life expectancy of 14.5 months.  Though impressive, these 
results do not seem to be consistent with the potential that the modality holds. 
 Since infiltrative tumors have single cells that migrate away from the main tumor, 
there is not as high a boron concentration in surrounding cells as is found in a cell in the 
midst of the tumor.  This is termed near neighbor effects.  This study endeavors to 
explore the effects of near neighbors by modeling both densely and sparsely boronated 
systems in a more realistic model of the cellular system.  This program has the possibility 
of being extended to evaluation of potential cellular damage and demise to structures 
other than the DNA in the nucleus. 
 The microdosimetry of BNCT allows exploration of the likely efficacy of boron 
carrier absorbing tumors to be modeled.  The results herein will demonstrate that some 
tumors will be more likely to be effectively treated than others.  In the cases of 
glioblastoma multiforme and malignant melanoma, the microdosimetry explains the 
modest clinical results for glioblastoma and good results for malignant melanoma.  
Further work on both the macro- and micro-dosimetry BNCT will help to guide the 
advancement of this exciting modality for cancer treatment. 
 x
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A. An introduction to and brief history of boron neutron 
capture therapy 
 
 In January of 1932, Irene and Frederic Joliot used a strong polonium source to 
explore a new penetrating radiation that was able to eject protons from a hydrogen rich 
paraffin layer.  Marie Curie and the Joliots attempted to explain the phenomena by using 
the recently described Compton scattering of the electron.  Using Compton scattering as 
the theoretical basis for their calculations led to a cross-section about 3 million times 
larger than that of the electron scattering for other known situations.  James Chadwick, 
who was working with Ernest Rutherford at the Cavendish Laboratory in Cambridge, 
realized that the interpretation of the data was incorrect and performed the same 
experiment using not only hydrogen as the target but also helium and nitrogen.  The three 
different targets allowed him to compare recoils and determine that the particles were 
neutral with a mass approximately equal to that of the proton.  Chadwick published his 
discovery of the neutron in the February issue of Nature.1  Shortly thereafter, M. 
Goldhaber collaborating with Chadwick,2 Taylor,3 and Burcham4 studied slow-neutron 
bombardment of the stable isotopes of boron, lithium, and nitrogen.  They found that the 
tracks from the disintegration of boron-10 were two short straight segments consistent 
with two heavy charged particles.  The average range of the particles was found to be ~8 
µm in the photographic emulsion.  These researchers would show that the actual reaction 
might be represented as two reaction channels: 
(I.A.1) 93.7%1 10 11 * 7 40 5 5 3 2n+ B B Li+ He+γ(0.48 MeV)+2.31 MeV→ →  
and 
(I.A.2) 6.3%1 10 11 * 7 40 5 5 3 2n+ B B Li+ He+2.79 MeV→ →  
where 11B* represents a metastable state that decays immediately by two reaction 
channels as shown in (I.A.1) and (I.A.2) where the percent probability of the reaction 
channel is in parentheses. 
 2
 Remarkably, boron neutron capture therapy (BNCT) was first proposed in 1936 
by the German biophysicist, G.L. Locher, of the Franklin Institute at Pennsylvania5 as a 
potential cancer therapy just four years after Chadwick’s discovery of the neutron and 
remarkably the same year that Taylor and Goldhaber described the 10B(n,α)7Li reaction.  
Locher examined the theoretical biological effects of these particles and realized the 
therapeutic potential of this reaction for cancer therapy.  Part of the attractiveness of this 
idea is that 10B has a large cross-section for thermal neutrons (~0.025eV) compared to 
some other isotopes likely to be found in human tissues as is shown in Table I.1.  Also, 
boron is non-toxic to humans even in large doses and 10B is stable.  
  It would be nearly two decades before this concept would actually be used in a 
cancer treatment for humans.  There was much research done in the years after the 
discovery of neutrons and the first human trials on the effects on cells seen after exposure 
to the several different types of radiation.  Researchers who saw BNCT as a potential 
cancer therapy were encouraged following the 1950 paper by Conger and Giles at Oak 
Ridge National Laboratory (ORNL).6  They were able to demonstrate the deoxyribo- 
nucleic acid (DNA) damage from the particles generated in the (n,α) reaction when lily 
bulbs containing boron were exposed to a beam of slow (thermal) neutrons.  This 
encouraged William Sweet and others at the Harvard University Medical School (HMS), 
 
 
Table I.1  Thermal neutron cross-sections for commonly occurring elements found 
in the body. 
Element % Relative Abundance Cross Section (barns) 
B-10    19.9 3840.0 
B-11    80.1           0.005 
C-12     98.89            0.0035 
N-14       99.634      1.8 
Na-23 100.0        0.43 
Cl-35    75.77   43.7 
K-39        93.2581    2.1 
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Massachusetts General Hospital (MGH), the Massachusetts Institute of Technology 
(MIT), and the Brookhaven National Laboratory (BNL).7  The Brookhaven Medical 
Research Reactor (BMRR) was constructed expressly for BNCT and contained a full 
clinical facility for onsite hospital care.  An excellent review of the early work in BNCT 
at HMS/MIT and BNL may be found in an article written by Sweet.7  As a neurosurgeon, 
Sweet wanted to treat the deadly, aggressive, and most common primary brain 
malignancy: glioblastoma multiforme (a carcinoma). 
 Glioblastoma multiforme (GBM) is truly a horrific killer that recognizes no socio-
economic factors, age group, race, or border.8  It arises from the brain’s supportive 
astrocytoma cells and is known as a high grade or Grade III (or IV in some grading 
systems) astrocytoma.9-11  The tumor is infiltrative in nature, which means that it extends 
by thin small streams of invasive cells analogous to the roots of a plant that infiltrate the 
soil.  Remarkably, a glioblastoma multiforme is often quite large before symptoms occur 
that lead to the discovery of the tumor.  The initial presentation is generally a fall, a 
seizure, or a subtle change in speech patterns.8  Additionally, many of these tumors have 
cells that undergo an amoeboid-like transition where the cells ‘swim’ through the brain to 
distant locations.  The cells that undergo an ‘amoeboid phase’ have been called 
infiltrative tumor cells (ITC)12 and account for the failure of all attempts to date to 
achieve long term survival.  This ‘amoeboid phase’ is the reason that the early neuro-
surgical attempts at a cure by performing a hemispherectomy were uniformly 
unsuccessful since the tumor spreads to the contralateral hemisphere.12-16  There are no 
known risk factors or genetic links to the development of GBM.10  The risk of developing 
a GBM is proportional to age until the latter years when the risk grows faster than age 
with the peak occurring in the 40 to 70 year age range.8  In the 1950’s the median life 
expectancy after the diagnosis of GBM was about 21 weeks.  The optimum therapy today 
consists of first performing debulking surgery to decrease the tumor burden with 
occasional placement of gliadel wafers, which contain an anti-tumor drug.7, 8  After a few 
weeks, the patient will undergo traditional photon therapy that consists of approximately 
36 treatments.  The patient will occasionally then have chemotherapy with BCNU 
(carmustine) or a similar alkylating agent.  Most recently, Ho, Lam, and Hui have used 
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gene therapy as well.17  All of this additional treatment has extended the median life 
expectancy after diagnosis to ~11 months (~44 weeks).16, 17  The course of the disease is 
one of progressive deterioration despite aggressive therapy so that the patient spends their 
most functional time going for treatments that often make them ill.  The time following 
the patient’s therapy is then characterized by a low functional status prior to the 
inevitable death.  Thus, there has been little improvement in the past 40 years in the 
quality of life for the glioblastoma multiforme patient despite a modest increase in life 
expectancy. 
 In 1950, the first human BNCT trials were started at the 20 megawatt research 
reactor just commissioned at BNL.  A thermal beam was created on the top of the reactor 
by removing some of the shielding.7  The theoretical calculations indicated that a 
concentration of 50 µg/g boron in the tumor and 15 µg/g boron in normal brain tissue 
would be sufficient to deliver 3 times the dose to the tumor as compared to the normal 
brain.  The first compound to be studied, borax (Na2B4O7⋅1OH2O), met that requirement 
with 15-20 µg of boron/g of brain resulting in tumor: brain boron ratios of 3 to 28 being 
obtained.7  The duration of the favorable ratios was short necessitating rapid treatment of 
patients.  The external carotid arteries were ligated in the 10 patients to receive BNCT 
along with tight elastic bandages applied to the scalp all to prevent damage to the 
vascular scalp.  The first five patients received a single fraction of radiation with the 
second five patients receiving 2 to 4 fractions.  The patients had no significant 
complications from the therapy and lived 6 to 21 weeks after treatment, that was 
equivalent to the best treatments available at that time.7  The autopsy results in six of the 
patients revealed little injury to the tumor but substantial damage to the scalp, which was 
often rather painful.  These results were correctly interpreted to indicate that few thermal 
neutrons were delivered to the tumor.7  Most thermal neutrons were deposited in the scalp 
and skull despite attempts to prevent this from happening.  These results prompted the 
construction of an operating room underneath the MIT Reactor II that was being built at 
the time.  The operating room would allow the scalp, skull, and dura to be surgically 
resected at the site of treatment and to be replaced after the treatment was completed.  
This would allow an improved thermal neutron flux to reach the tumor. 
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 Parallel to the efforts to improve the delivery of thermal neutrons to the tumor 
was the development, beginning in 1958, of improved delivery systems for the boron-10 
isotope by A. H. Soloway and his colleagues.  Soloway’s team was able to develop 
models for the brain’s protective mechanism known as the blood brain barrier (BBB), the 
tight junctions between vascular endothelial cells that prevent the diffusion of most 
substances.18  With their models, the researchers were able to prepare boron carriers that 
were of low toxicity and could cross the BBB at least to some extent.  It was understood 
that the GBM would damage the BBB but that GBM cells far removed from the tumor 
body would depend on diffusion across the BBB in order to receive a sufficient boron 
concentration to provide a lethal radiation dose.  They synthesized p-
carboxyphenylboronic acid which was used in the next 16 patients; the last two patients 
were treated with sodium perhydrodecaborate (Na2B10H10).19, 20  Sodium 
perhydrocarborate was the most soluble, biologically inert, and stable chemically that 
Soloway had developed to that date. 
 The second BNCT trials, which took place at the MIT Reactor, involved a total of 
18 patients who lived from 10 days to 11½ months post BNCT.  Of those 18 patients, 14 
underwent postmortem examinations of their brain.  The findings included extensive 
radiation necrosis of the brain in nine of the cases, and in only two of the cases recurrent 
tumor was seen.21  In a single patient, there was found to be extensive radiation necrosis 
and tumor.  Of the 14 postmortem brains examined, only in one of the 11 glioblastoma 
patients were islands of glioblastoma no longer seen.  This particular patient had a 
neutron fluence measure at the surface of the brain of 1.1 x 1013n/cm2.  This fluence was 
the third highest among the doses given in this series of patients.  The patient had a 
radiation time of approximately 45 minutes which was less than half the longest 
treatment time, and the dose of 25 mg/kg of 10B was slightly less than 30 mg/kg given to 
eight of the patients.  At the time, the conclusion was that this tumor was less radiation 
resistant than most of the series.  Unfortunately, as is often the case, data pertaining to the 
boron levels in the blood, normal brain, and tumor were not available.  Finding patients 
who respond well to therapy despite being given less than maximal doses of BNCT is a 
theme echoed in later studies. 
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 As had been true in the first studies, thickening of the blood vessel walls occurred 
due to endothelial cell proliferation and enlargement of their cells.  This endothelial cell 
proliferation and enlargement resulted in vascular occlusion, which was termed 
‘coagulation necrosis’.  This coagulation necrosis had never been seen before and so was 
especially remarkable to the researchers.22, 23  It was characterized by devitalized tissue 
rather than the usual liquefactive chain of events that took place with irradiation of blood 
vessels.  The interpretation was that the fissioning of the boron in the blood stream 
induced vascular changes that resulted in coagulation necrosis.  This result showed that 
any boron delivery agent would have to clear the vasculature somewhat prior to 
irradiation to avoid coagulation necrosis.  Obviously, this can cause damage to normal 
tissue as well as the target malignancy.  Work by Kitao24 of the National Institute of 
Radiological Sciences in Japan, and by Rydin, Deutsch, and Murray25 at MIT resulted in 
calculations that showed that, as a rule of thumb, the radiation dose to the vessel wall is 
comprised of one-third from the intra-luminal concentration of boron and two-thirds from 
the extra-vascular boron level.  At this particular time in history, it was difficult to rapidly 
determine boron levels in the blood or tissues and many times researchers had to wait 
several days for the results to be obtained.  Based on their best calculations the doses 
delivered were increased resulting in a patient who received a much higher dose than 
their initial calculations would have indicated.  This was a consequence of measuring the 
boron at the time of treatment although the treatment plan had to be based on prior 
measurements.  This unfortunate patient received a much higher dose than was prescribed 
resulting in the patient’s death of cerebral edema some 10 days after treatment.7  At that 
time, the clinical trials were stopped due to lack of an agent that would allow rapid 
detection, delivery of adequate amount of boron to the target tissue, and a safe level of 
boron delivered to normal tissues. 
 Identifying a compound that satisfied the above-noted requirements took much 
longer than had been anticipated.  Twenty-four years later, Ralph Fairchild and his 
colleagues at Brookhaven National Laboratory, came up with a solution to this problem.26  
They were able to measure the concentration 10B, which is only about 20% of the 
naturally occurring mixture of 10B and 11B.  This technique is based upon the existence of 
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a 478 keV γ-ray that occurs 94% of the time in disintegrations of 10B.  This γ-ray is given 
off immediately at the decay of the metastable 11B, which has a half-life on the order of 
nanoseconds.  The thermal neutrons that are required to make the determinations were 
obtainable directly from the reactor where the therapies are done. 
 The disappointing results of the MIT studies encouraged Soloway, who was now 
joined by H. Hatanaka, to continue looking for new and improved boron delivery 
compounds.  By 1967, they had screened more than 150 compounds trying to find the 
best one for BNCT.  They developed a compound called BSH (B12H11SH2-), which was 
found to provide tumor:normal tissue boron ratios ranging from 1.4 to 20.27  
Unfortunately, BSH and its metabolic products were found to bind to serum albumin, 
which leads to coagulation necrosis problems.  Additionally, BSH was shown to be 
somewhat toxic.  Slow I.V. injection of 240 mg of boron/kg over five days at a rate of 40 
mg/kg/day was, however, found to result in no toxic effects.  After much work, a stable 
form of BSH for human use was developed by researchers at MGH.28  At Shiongi, 
Hatanaka and colleagues purified and stabilized the BSH.29  That permitted the use of this 
compound as a boron carrier for the series of 140 patients done by Hatanaka. 
 Hatanaka had been working with Sweet and at others at Massachusetts General 
Hospital and MIT during some of the early years of BNCT.  He later spent time at MIT 
working on the clinical trials concluding in 1967.  Hatanaka took the idea of BNCT back 
to Japan with him.  Being a neurosurgeon, he also had a great desire to try to cure 
malignant gliomas.  In one series of experiments, he treated 40 patients with BNCT and 
the other 50 by multimodality combination of fractionated photon radiotherapy and 
chemotherapy.29  The BNCT group had a five-year survival rate, four times that of his 
multimodality group despite being 10 years older on the average.  This is a rather 
remarkable accomplishment considering that Hatanaka had only a 100 kW reactor in 
contrast with the multi-megawatt reactors available in the United States at the time.  
Hatanaka realized early that tumors greater than approximately 6 cm would probably 
receive an inadequate dose of thermal neutrons due to the inability of the beam to 
penetrate that deep.  Therefore, Hatanaka was delighted to report a five-year survival rate 
of 58% for patients with glioblastoma multiforme, having relatively superficial tumors.30, 
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  This is very remarkable considering that the five-year survival rate reported by Charles 
Wilson in 1991 for his 449 patients with a diagnosis of glioblastoma at first operation 
was 4.7%.32  Wilson’s patients were treated by radical surgery plus radiation and 
chemotherapy.  Hatanaka, for this pioneering work, is in many ways the father of BNCT.  
It is his early success that has spurred interest in the field. 
 Yutaka Mishima and his collaborators, beginning in 1972, started experimenting 
with boronated tyrosine analogs as boron carriers for neutron capture therapy.  The idea 
was originally to attack the problem of malignant melanoma.33, 34  However, it was found 
that the boronated phenylalanine also preferentially concentrated in glioblastoma, as well 
as in malignant melanoma.  The 10B-L-p-boronophenylalanine (10B-BPA) is rather 
insoluble, making its delivery to human beings rather difficult.  This was solved by 
creation of a fructose complex.  It has been found that even very high doses of 10B-BPA 
are innocuous to human beings.35 
 The early days of BNCT were marked by difficulties in determining neutron 
fluence, penetration, and composition of the beam.  The lack of an adequate boron carrier 
certainly plagued the early studies and continues to be a problem today.  Unlike other 
early modalities such as radiation therapy, chemotherapy and, more recently, 
immunotherapy, BNCT has been used only for a very limited number of tumors.  To date, 
the only clinical trials have been with glioblastoma multiforme, malignant melanoma, 
and a single patient with metastatic carcinoma of the colon.  This situation is unlike other 
modalities of cancer therapy and, as will be seen, has caused problems for the field of 
BNCT. 
 
B. A review of recent boron neutron capture therapy clinical 
trials 
 
 Hatanaka’s results were summarized and published in the 1980’s.31, 36, 37  At that 
time, in the United States, BNCT had been languishing due to the poor results of the 
initial clinical trials.  Lack of funding had prevented researchers in the field from 
developing new compounds and, though the work continued on developing better beams 
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and detection methods, no further clinical trials were performed.  However, Hatanaka’s 
results received worldwide attention.  Certainly, his claim to have a twenty-year survivor 
of glioblastoma multiforme was unheard of with other modalities.38  However, there were 
some concerns about Hatanaka’s data raised by Larramore and Spence39 which will be 
discussed below in some detail.  Despite these concerns, interest in BNCT in the United 
States and Europe was revived. 
 Clinical trials were resumed at Brookhaven National Laboratory as well as at 
Harvard and MIT in the early to mid 1990’s.  Under J. A. Coderre, Brookhaven clinical 
trials were begun in September 1994 concluding in May 1999.40  P. M. Busse at Harvard 
and MIT conducted clinical trials from mid 1996 until May 1999.41  Prior work had found 
that BSH does not cross the blood-brain barrier and is typically renally excreted 
unchanged.42-45  BSH is toxic in large doses with rapid infusions due to the ionic effect.  
It concentrates in GBM over normal brain tissue at about a ratio of 3.5-4.5:1.  BPA, on 
the other hand, was found to be nontoxic in even very large doses and is also renally 
excreted unchanged.35, 46, 47  BPA also concentrates in the glioblastoma in a ratio of about 
3.5-4.5:1 but it does cross the blood-brain barrier which means that it has a greater 
opportunity to reach the infiltrative tumor cells.48-50  Unlike the blood concentration in 
BSH that takes one to two hours to decrease, the blood concentration for BPA diminishes 
very rapidly.  Thus, in the United States and in most places in the world, BPA has 
become the primary boron carrier for BNCT.  Barth et. al. have experimented with 
compounds to disrupt the blood-brain barrier with mixed results.50-53 
 The clinical trials at Brookhaven National Laboratory were designed to evaluate 
the tolerance of the central nervous system BNCT.  A total of 53 patients in eight 
different phase I/phase II protocols were evaluated.54  All of the patients received BNCT 
with BPA using 1, 2 or in some cases 3 radiation fields.  A single patient was retreated 
(referred and managed by T. L. Nichols).  The entry criteria for the Brookhaven trials 
required that the tumors be supra-tentorial, unilateral, unifocal, and surgically resected.  
There could be no evidence of congestive heart failure, the Karnofsky Performance Score 
had to be 70 or greater, and normal blood chemistries were required, in general that being 
a white count of around 2500/mm3, a platelet count of 75,000/mm3, and a creatinine of 
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1.6 mg/dL or better.  All patients had to be 18 years of age or older.  No separation was 
made on the basis of sex or race.  There could be no history of phenylketonuria, prior 
radiation therapy to the brain, prior immunotherapy, and systemic or intrathecal 
chemotherapy prior to BNCT.  Informed consent was obtained for all subjects.  The 
results of this trial were reported for this group, at the Tenth International Symposium on 
Neutron Capture Therapy for Cancer in Essen, Germany in 2002.40  All patients had died 
but the mean survival times were reported as 64.1 weeks for one field, with dose ranging 
from 8.9 to 14.8 Gy-eq; 52.4 weeks for two fields with a dose of 11.3 – 14.2 Gy-eq, and 
51.6 weeks for three fields with a dose of 12.6 – 15.9 Gy-eq.  It is important to note that, 
as the trials progressed and the dose progressed and the fields increased, the trials 
included patients with increasingly large tumors.40, 55  Brookhaven also reported that the 
time to progression for the tumor was 34.5 weeks for one field, 21.1 weeks for two fields, 
and 18 weeks for three fields.  This result is odd because the time to progression shows a 
negative dose response.  This is unlike typical findings for radiotherapy, where increasing 
the dose gives an increased survivability, at least up until the time that radiation damage 
to normal tissue exceeds the benefits of the treatment.55  This rather perplexing result as 
well as the example of some of the earlier data are not yet fully explained.  The treatment 
planning for the Brookhaven National Laboratory trials was performed with a set of 
codes developed at Idaho National Engineering and Environmental Laboratory by Nigg 
and his colleagues.56-60  The program solves the Boltzmann transport equation for 
neutrons and produces dose contours based upon the structures and composition of the 
brain.  The results of the isodose curves are then scaled linearly for the presence of boron.  
This has been shown to hold true for boron concentrations in the realm that are currently 
being achieved in BNCT.  Namely, boron concentrations up to ~100 ppm will allow 
linear scaling with only small errors. 
 Simultaneously efforts were underway at MIT under the direction of Zamenhof to 
develop a treatment plan code entitled MAC-NCT Plan.61-63  This treatment planning 
package was used to do all treatment planning and report doses for the patient’s treated at 
Harvard/MIT.  Relatively recent work has shown that these two codes are compatible, 
yielding similar results if the input neutron beam specifications are the same.64, 65 
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 The Harvard/MIT phase I trial was designed to determine the maximum tolerable 
dose to normal tissue for cranial BNCT irradiations.  Although this trial did incorporate 
dose escalations to be given to the patients, there was no phase II portion planned.  The 
patient eligibility was similar to that at BNL in that the patient had to have a biopsy-
proven and resected glioblastoma multiforme.  They would also treat patients with 
multiple brain metastases of biopsy-proven malignant melanoma as well as treating 
malignant melanoma confined to the arms or legs.66, 67  As in the case of the BNL trials, 
the patient had to have a Karnofsky Performance Score of 70 or greater, no history of 
prior intracranial irradiation, no previous chemotherapy, no history of phenylketonuria, 
be 18 years or older, and all patients had to provide informed consent.  The patients were 
given BPA through an I.V. infusion through a central venous line at doses of 250 mg/kg 
over 60 minutes, up to 300 mg/kg over 60 minutes, or 350 mg/kg over 90 minutes.  The 
initial dose was 8.8 Sv and was increased by 10% after every three subjects were treated.  
Twenty-four patients were entered in the trial, 22 were irradiated, and two subjects were 
excluded due to decline in performance status by the time of arrival at Harvard.  Of the 
irradiated subjects, two had metastatic melanoma.  The remainder had glioblastoma 
multiforme.  The median age was 56 with an age range of 24 to 75.  Six dose cohorts 
were completed at doses of 8.8, 9.7, 10.6, 11.7, and 12.8, and 14.2 RBE-gray.  Depending 
on the location of the tumor for the particular dose cohort, one to three radiation fields 
were used.  According to Busse, “of those patients surviving beyond six months, no MRI 
white matter changes were observed and no long-term complications attributable to 
BNCT were evidenced”.41  No survival data have been reported on these phase I trials, 
but via personal communication, they are comparable with the experience from BNL 
with median life expectancies on the order of 14 months.68 
 In the mid 80’s, Hatanaka died and his collaborators continued the trials with 
BNCT being the current treatment of choice for glioblastoma multiforme in Japan. The 
Japanese also employ BNCT for the treatment of malignant melanoma involving the 
extremities.  The Japanese continue to report long-term survival rates higher than the 
trials seen at Brookhaven and at Harvard,69 which may be partially accounted for by their 
continued use of a thermal beam rather than the epithermal neutron (1 eV-10 keV) beam 
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employed at BNL and MIT.70, 71  Epithermal beams of neutrons with their slightly higher 
energies allow neutrons to penetrate further, thermalizing by the time they reach the 
depth of the tumor.  The Japanese solved this problem a different way by continuing to 
use a thermal column and, reflecting the scalp and the skull prior to irradiation.  Also, 
after debulking neurosurgery for the glioblastoma, they filled the void created with 
essentially a ping-pong ball.  It is believed that this may provide better uniformity of dose 
and cause less attenuation of the thermal neutron beam. 
 There has been much interest in the Japanese data.  The neuropathologists George 
E. Laramore and A. M. Spence at Washington State University have re-analyzed some of 
the Japanese data.   Laramore took the Japanese results and tried to identify patients who 
were from the United States.  On that cohort of patients, he was able to obtain original 
pathology reports.  He reevaluated those cohorts and felt that some were misdiagnosed.  
They claimed that many of the pathologic diagnoses were not accurate and that the 
patients also had lymphomas and other malignancies.  When re-evaluated, he stated, “The 
only long-term survivors in the BNCT group had anaplastic astrocytomas and favorable 
prognostic criteria” (classes I and II of Curran et. al.).39  The patients that Laramore felt 
did not meet the criteria for glioblastoma multiforme, had a three-year survivability rate 
of 22% versus 13% for ‘correctly’ diagnosed patients whom they agreed had a GBM.  
Two-year survivability for the non-GBM patients was 20% versus 10% for the GBM 
patients.  Thus when the disputed patients were removed, the cohorts with GBM had 
results like patients in other trials.  These findings therefore cast some doubt upon the 
Japanese results.  He was unable to obtain any other data from the Japanese; therefore, 
the Japanese results present something of a conundrum.  It is prudent to remember that in 
grading (and therefore determining the classifications) of high-grade astrocytomas, the 
actual grade is rather subjective in nature.  The relative disorganization of the tumor 
tissue and the relative abnormality of the nuclei determine the grade awarded it by the 
pathologist.  Also, it should be noted that the patients would have had to have an initial 
pathological diagnosis of a GBM by a pathologist in the USA prior to being sent to Japan 
in the first place.  Furthermore, a Japanese pathologist would have reviewed the 
pathology slides prior to any treatment.  Therefore, with the subjective nature of the 
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process, a definitive answer may have to await other studies to determine the actual 
results of the Japanese experience.  The more recent Japanese results are, though still 
better than most other centers comparable to other results.69 
 The Brookhaven National Laboratory experience with BNCT yielded a life 
expectancy of 14.2 months in their cohort of 53 patients.40  One patient of interest was the 
only patient in the world to be treated twice with BNCT and she was a referral from The 
University of Tennessee (UT) research program to BNL.  She was one of six 
glioblastoma multiforme patients referred from UT to either Brookhaven National 
Laboratory or Harvard/MIT.  (A seventh patient was sent to Harvard/MIT with multiple 
brain metastases from malignant melanoma.)  This GBM patient was an active retiree 
who swam on a regular basis.  She had had her GBM resected at a local hospital and did 
not want conventional radiation or chemotherapy.  She was referred to Brookhaven 
where she received a single dose treatment of BNCT.  Thereafter, she immediately 
resumed her active lifestyle having only minor alopecia in the region of the irradiation, 
and some mild problems with mucus gland swelling on the left side of her face where her 
left parieto-occipital GBM was irradiated.  She remained active post BNCT with very 
little interruption into her normal schedule.  In fact, it was rather difficult to get her to the 
office for scheduled appointments for the clinical trials due to her busy schedule.  
Approximately 10 months following her initial debulking surgery, she developed some 
depression, lethargy, and according to family members, a mild change in her affect.  She 
was then referred a neurosurgeon at the University of Tennessee Medical Center who 
noted regrowth of the tumor adjacent to the initial tumor site.  This tumor was once again 
resected and she was sent back to Brookhaven for a second irradiation.  Once again the 
treatment was accomplished with no obvious ill effects except for mucositis, mild 
alopecia, and reddening of the scalp.  She required steroid treatment with dexamethasone 
following the resection and following both treatments with BNCT.  She died about four 
months after her second BNCT treatment, surviving a total of about 14 ½ months from 
the time of diagnosis.  Of great interest, however, are her pathology reports.  The initial 
pathology report was read as 95% of the specimen consistent with glioblastoma 
multiforme and approximately 5% consistent with a gliosarcoma.  Gliosarcomas are 
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much more rare than glioblastomas and have no known effective therapy and are 
extremely aggressive.  The biopsy from her second resection showed quite the opposite 
situation.  There were almost no elements of glioblastoma multiforme seen and those that 
were seen appeared to be necrotic.  The remainder of the tumor was consistent with 
gliosarcoma.  As with all of the patients who received BNCT through UT Medical 
Center’s referrals to the two clinical trial centers, the patients had virtually no ill effects 
except for some mild alopecia and mucositis.  In all cases, the patient and the family were 
pleased with the treatment.  This case does illustrate some of the problems in interpreting 
the biopsy data for this complicated disease and understanding the disease process. 
 The renewed interest in the United States in BNCT also sparked increased interest 
worldwide.  Since the time that the US trials restarted, programs have begun in Sweden, 
Finland, the Netherlands, Romania, Italy, and Argentina.  Most of these trials utilize BPA 
as the boron delivery agent.  Most of the trials are treating glioblastoma multiforme but 
Harvard also treated malignant melanoma, as are the Japanese.  The Japanese are using 
BNCT as the treatment of choice for GBM and have started exploring the possibility of 
treating hepatocellular carcinoma72 and pancreatic carcinoma.73  Undifferentiated thyroid 
carcinoma as well as other head and neck tumors has been explored by a group in 
Argentine.74  The Italians are treating carcinoma of the colon75, 76 and head and neck 
tumors at their TAPIRO BNCT facility.77  The Italian effort deserves some discussion.  
They have recently explanted a liver after loading the patient with BPA.76, 78, 79  The liver 
was then taken to a nearby reactor, which has only a thermal neutron beam available.  
The liver contained at least 22 distinct metastases of carcinoma of the colon.  As is well 
known, this large a tumor load of the liver is virtually an untreatable situation.  The liver 
was then irradiated by the thermal neutrons and reimplanted.  The patient lived ~4 years 
post BNCT with signs of regression of all liver lesions but dying of disease elsewhere as 
related personally.  There were no known ill effects other than the typical surgery 
morbidity with the explantation, irradiation and reimplantation.  Thus, BNCT is being 
applied to many different malignancies where it may become a valuable, if not, lifesaving 
treatment.  It is well recognized that two great advantages BNCT has compared to 
conventional radiation therapy are that a much larger dose is delivered to the tumor and 
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that doses are delivered in a single or small number of fractions.  So that the patient 
spends less time meeting in a health care setting since for terminal conditions, the patient 
will have more time for themselves and their family. 
 Another case may help illuminate some of these points.  The patient was an active 
53-year-old white male elementary school principal from middle Tennessee.  He had 
been found to have a primary malignant melanoma on his back.  For reasons that are not 
clear, there was a delay after the initial biopsy in undertaking definitive therapy of several 
months.  By this time, he had developed a massive melanoma tumor load in his chest and 
had four distinct intracranial metastases as indicated by positron emission tomography 
(PET).  The patient, when apprised of his grim diagnosis, looked for alternative therapies 
and was referred to the program at Harvard.  From Harvard, he was referred to UT 
Medical Center for positron emission tomography imaging and subsequent management 
of his thoracic tumor load following intracranial BNCT.  Of interest, the four lesions 
were not clearly seen on CT or MRI but were readily seen with PET.  The patient 
underwent BNCT in late October, receiving his intracranial irradiations in three fractions 
on Wednesday and Thursday of that week.  He returned home to play golf on Sunday and 
was back to work on Monday morning.  The patient did very well following the 
irradiation, being placed only on dexamethasone.  His only ill effects from the BNCT 
were local alopecia and some very mild mucositis.  Approximately one month following 
BNCT, the patient entered UT Medical Center for chemotherapy and immunotherapy for 
his large thoracic tumor load of melanoma.  It should be emphasized that there is no 
known effective treatment for metastatic malignant melanoma of the brain with more 
than a single focus.  Therefore, the immuno- and chemotherapy that were begun would 
not be expected to significantly affect the course of the brain metastases but only that of 
the tumor load elsewhere in his body.  Unfortunately, following his initial dose of 
chemotherapy and immunotherapy, the patient developed sepsis from his immuno-
suppression.  He quickly developed adult respiratory distress syndrome (ARDS) resulting 
in intubation and mechanical ventilation.  He had a long and complex stay in the 
intensive care unit during which time he also developed acute renal failure requiring 
hemodialysis.  His renal function did improve after several weeks of dialysis and his 
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kidney function gradually returned.  However, his mental status did not improve as much.  
He was never fully cognizant of his surroundings or others following his extubation.  
After an MRI was read as having multiple micrometastases of malignant melanoma, the 
family decided not to pursue further treatment and he was discharged to a nursing home 
where he died a short time later.  Upon his death, approximately five months post BNCT, 
a limited postmortem was done upon his brain alone.  His death was due to the thoracic 
tumor load.  The postmortem examination of the brain revealed that what was thought to 
be micrometastases of melanoma was actually a saponification related to the ARDS.  All 
four of the malignant melanoma metastases were found to be necrotic and were 
involuting.  There was no evidence of other intracranial melanoma and the melanoma 
present was in the process of dying.67  This patient had a similar course as the first patient 
treated at Harvard for melanoma of the brain who survived a year after BNCT.  This 
patient had evidence of complete resolution of melanoma in his brain but died due to 
tumor load elsewhere in his body.66 
 The results from the worldwide clinical trials for BNCT to date are difficult to 
interpret.  The American experience would only show a modest increase in life 
expectancy for glioblastoma multiforme patients.  In the case of malignant melanoma, 
there is reason to believe that brain metastases could be cured, although the tumor load 
and the rest of the body may still overwhelm the patient.  The Japanese experience is 
more positive than that of the American but there are detractors who represent competing 
therapies (fast neutron therapy).  The European experience is still in its infancy but the 
Finns now have a commercially viable BNCT program.  The Italians, Japanese, and Finns 
are opening exciting new vistas by applying BNCT to different tumors.  When examined 
from the perspective of a GBM patient or a patient with multiple melanoma brain 
metastases, BNCT is already a success.  This is not due to BNCT adding time to the life 
expectancy, but is rather because it provides a short and serious complication-free 
treatment that allows the patient to enjoy the best quality of life that can be provided from 
these horrific diseases. 
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C. A brief review of problems encountered in boron neutron 
capture therapy 
 
 As may be inferred from the above discussion, there are four factors that will 
ultimately determine the effectiveness of BNCT.  The first two deal with the beam 
quality.  It is estimated that the fluence of thermal neutrons in the tumor region needs to 
be on the order of 1012 which corresponds to a flux of about 109 neutrons per second.80  
Less flux will result in unreasonably long irradiation times and more flux will likely 
increase the toxicity without increasing the tumor dose.  The other issue is the beam 
quality.  It is well known that fast neutrons are harmful and other beam contaminants 
such as γ-rays and other ionizing particles can change the delivered dose, sometimes 
dramatically.  In order to achieve the best efficacy, a flux of neutrons which is thermal at 
the depth of the tumor, a pure beam of epithermal neutrons is requisite.80  Due to 
difficulties in neutron beam measurement in the 50s and early 60s, this was difficult to 
achieve.  However, it is now felt that available beam quality is more than adequate.  The 
neutron beams have few other types of ionizing radiation and are typically epithermal in 
nature so that the neutrons will be thermalized by the time they reach the depth of the 
tumor.81-86  Fluences are now commonly achieved in the 5 x 1012 range.87-89  At this point 
in time, no significant advances are required in beam quality or fluence.  The other two 
issues that relate to the efficacy of BNCT have to do with the delivery of boron-10.  The 
delivery method must first of all be relatively nontoxic in nature.  For some boron 
containing molecules (i.e. BPA), in order to achieve sufficient tumor to normal tissue 
ratios, large amounts of infusate over a long periods of time are required.  A compound 
and all its active metabolites must have low toxicity.  Lastly, the boron containing 
molecule must concentrate preferentially in tumor cells over normal tissue in a ratio of at 
least 3:1.90  That will ensure that approximately three times the dose will be deposited in 
tumor cells rather than normal tissue.  In order to prevent coagulation necrosis, the 
vascular washout needs to be complete or nearly complete at the time of irradiation.  In a 
tumor such as glioblastoma multiforme that has infiltrative tumor cells (ITC)12 that may 
be far away from the main body of the tumor, a 3:1 ratio of boron in all tumor cells to 
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compared normal tissue must be attained.  Obtaining a favorable boron ratio in these 
ITCs is a much more difficult criterion to meet. 
 In traditional radiation therapy, treatment plans are produced showing isodose 
curves.  These treatment plans provide the macrodosimetry for that particular radiation 
modality.  In BNCT, the major irradiation dose is variable throughout the tissues partially 
due to the variation in nitrogen concentration through the (n,p) reaction and primarily due 
to significant concentration differences for in 10B through the (n,α) reaction.  If there is a 
sufficient boron concentration (approximately 15 µg normal tissue and 50 µg or more in 
the tumor), the (n,p) and (n,α) reactions account for more than two-thirds of the total 
radiation dose.91  Other significant reactions are from the proton recoil from hydrogen, 
carbon recoil, and the γ-rays given off from the 10B reaction.  The proton recoil from the 
1H(n,γ)2H reaction has a small thermal neutron cross-section of only 0.332 b and will 
produce a somewhat homogeneous dose due to the ubiquitous hydrogen distribution.  The 
range of the carbon ion recoil from the 14N(n,p)14C reaction is only ~0.26 µm.   The γ-
rays are produced isotropically from the 1H(n,γ)2H and 10B(n,α γ)7Li reactions and have 
long ranges with much of the energy deposition occurring outside of the brain.  The most 
significant variability in dose will be delivered by the protons, alpha particles, and 
lithium nuclei from the 14N(n,p)14C and 10B(n, α γ)7Li reactions.  The essential treatment 
failure in BNCT at this time is due to an inadequate concentration of boron in the tumor 
cells as compared to normal tissue.  This manifests itself as either a lack of sufficient 
therapeutic ratio (3:1 or better) in tumor cells to normal cells or due to a lack of total 10B 
concentration.  Analysis of studies in the literature and discussions with the researchers in 
this area would seem to indicate that the problem is in both of these areas.41, 60, 63, 69, 92-102 
 Previously, treatment planning was performed either by extrapolation from animal 
models such as dogs and mice or by utilizing data taken at the time of initial 
neurosurgical debulking surgery.  These two sources have provided all of the data about 
the 10B distribution and also present problems.  For animal models, it is unclear how the 
results should be scaled to the humans especially in regards to the active and passive 
diffusion rates of the boron containing compound.44, 103-108  The problem is different for 
the neurosurgical debulking data.  Since this is human data, the concerns with diffusion 
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rates and scaling are not a factor.109-116  A description of the data acquisition follows.  
After obtaining informed consent and just prior to the patient’s surgery, the patient is 
loaded with 250 mg BPA/kg of IV BPA.117  At the time of debulking surgery, the 
pathological specimens are divided between the pathologist and the BNCT researcher 
from BNL.  The pathological specimens provided to BNL were analyzed for absolute 
boron content.111, 114, 115, 118  While this provides information about boron distribution 
within the tumor itself, no information is gained about the boron concentrations at other 
locations in the brain – even near the tumor.54  Because the neurosurgeon will not inflict 
more harm than is necessary, little normal tissue from around the tumor has ever been 
sampled.  This means that inadequate information was obtained to model the 10B 
concentration in the surrounding tissues.  Adding to the problem was the logistics.  
Patients were often far from BNL or were referred for BNCT after debulking surgery had 
been performed.  Thus, few patients had data regarding the boron concentration.  
However, for most of the trials, data obtained by Coderre indicated a tumor to normal 
brain concentration of 4.5 to 1 has been used in treatment plans.94, 111, 114, 117-126  Another 
problem with data obtained at the time of debulking surgery is that the tumor physiology 
is altered by the disruption caused by the surgery itself.  The tumor size, blood supply, 
and relationship to surrounding tissues are different at the time of BNCT several weeks 
after the debulking surgery.  Therefore, whatever the concentrations of boron found at the 
time of debulking surgery, they will likely not reflect the actual concentrations at the time 
of BNCT.54  Also, the vascularity may increase or decrease depending on multiple local 
factors that cannot be determined as well as the integrity of the blood brain barrier.  
Therefore, the boron concentration ratio of 4.5:1 for the residual tumor to the surrounding 
normal brain is not likely to be obtained for most patients.  Thus, the treatment planning 
(macrodosimetry) problem in BNCT presents many challenges.  Inadequacies in this area 
could lead to inadequate dosing to certain areas of the tumor and tumor containing 
regions as well as over dosing of normal surrounding tissue.  A typical treatment plan for 
BNCT generated by the code SERA developed at INEEL127 using the 4.5:1 tumor to 
normal tissue boron ratio is shown in Figure I.1. 
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Figure I.1  A typical SERA generated treatment plan for a glioblastoma multiforme 
based upon a MRI image.  The tumor is the white area inside the ellipsoid like curves.  
The curves are isodose lines indicating predicted tumor killing.  The innermost line is the 
95% isodose curve indicating that 95% of tumor cells within the curve will be killed.  
The remaining curves represent 5% intervals. 
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 The goal of treatment planning is to take into account the clearly demarcated 
tumor, and to develop a treatment plan in which the isodose lines of 90% kill lie 
approximately of 2 cm outside the tumor margins.102, 127 
 In later trials, investigators included the edematous region around the tumor, 
which is known to have many tumor cells.  In Figure I.1 one can see oval isodose curves 
with the 55% curve encompassing most of the brain.  Unfortunately, the clinical trials 
found that most recurrences occurred in tissues immediately adjacent to the visible 
tumor.40, 41, 54  With the current macrodosimetry model, this is a puzzling result since the 
central areas within the 90% kill range are often receiving in excess of 60 gray 
equivalents of radiation.40, 41, 69, 128  That is a large radiation dose that should be lethal to 
any cells within that range that are loaded with boron.  These results indicate that the 
region of interest (the targeted tumor region and surrounding edematous region) is not 
actually receiving the dose that the treatment plan predicts.  Therefore, a better way of 
determining in vivo boron concentration is needed. 
 In addition to solving the macrodosimetry problems, more efficacious boron 
delivery compounds must be found.  There has been much work in compound 
development over the world in the last 30 years. Many promising delivery agents 
(including monoclonal antibodies) have been created as well as mechanisms to improve 
delivery of currently employed agents (BPA and BSH).129-166  Unfortunately, either there 
is toxicity from the compounds and their metabolites or there was inadequate 
discrimination between tumor and normal tissue.  BPA is still the boron delivery system 
of choice for most BNCT (especially for melanoma since phenylalanine is a precursor to 
melanin), which means that, at least for glioblastoma multiforme, it appears to be 







D. Treatment planning with 18fluoro-boronophenylalanine 
positron emission tomography scans for boron neutron 
capture therapy  
 
 In the 1970s, Phelps and Ter-Pogossian developed the technique of positron 
emission tomography as a possible imaging technique.167-170  The technique uses a 
positron emitting nuclide attached to a carrier molecule.  Although ammonia and water 
have been used for PET, the most commonly used molecule is fluorodeoxyglucose 
(FDG) which is a sugar that distributes like glucose.  The emitted positron annihilates 
when it encounters an electron producing two 511 keV γ-rays at 180 degrees to each 
other.  The common positron emitting nuclides employed in PET are the four short half 
isotopes: carbon-11 (t1/2~20min), nitrogen-13 (t1/2~10min), oxygen-15 (t1/2~2min), and 
fluorine-18 (t1/2~110min).  After the positron emitter is produced in a cyclotron, it is 
chemically attached to a carrier compound.  For example, fluorine-18 produced in a 
cyclotron, is chemically combined with glucose to form fluorodeoxyglucose.  As with 
glucose utilization, the fluorodeoxyglucose is preferentially transported into the most 
metabolically active tissues.  Therefore, the most metabolically active tissues have high 
glucose utilization, which means that the FDG collects in the same tissue.  The images 
were obtained by filtered back projection of the coincidence counts in the PET scanner.  
The resulting images provide a metabolic distribution map of the structures imaged.  For 
example, a positron emission tomography scan of the brain would show the most intense 
activities in areas that are active at the time of the scan.  So, when the eyes are open, 
increased activity is seen in the occipital region.  Unlike MRI, CT, ultrasonography, and 
plain x-rays, PET scanning allows the determination of dynamic information about a 
tissue.   The first clinical PET center in the country was established at the University of 
Tennessee Medical Center in the late 1980s.  Kabalka at UT and Ishiwata in Japan 
realized that the 18F could be successfully added to BPA to form 18F-BPA (2-fluoro-4-
boronophenylalanine).116, 171-174  Pharmacokinetic studies show that fluorine stays 
attached to the BPA until the complex is renally excreted175, 176 so that PET scans identify 
the 10B distribution.116  Thus, the in vivo boron distribution can be determined for BNCT 
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patients.  The patient can be imaged after healing from debulking surgery and prior to the 
BNCT.  Figure I.2 is a PET scan of the same patient shown in Figure I.1 that was 
generated using 18F-BPA.  The GBM is the oval in the lower left portion of the scan. 
 The information contained in the PET scan may be directly correlated with the 
boron content in the brain.  The patients were infused with only 10 mCi of activity, which 
contributes to the graininess of the images. The other source of graininess in PET images 
is due to the fact that a positron moves up to 10 mm prior to annihilation. 
  Since the positron emission tomography scan is a boron distribution map, this 
information can be used to scale the results of a treatment plan generated by one of the 
standard BNCT treatment planning programs.  The treatment plan in Figure I.1 was 
redone with the PET data input into SERA to provide the boron concentration throughout 
the brain.  Since the total boron concentration never gets as high as 100 ppm anywhere in 
the brain, it is possible to use these data in post-process scaling.  When this is done, 
dramatic differences in the isodose contour lines are seen as shown in Figure I.3.  The 
contours are much more closely packed and irregular which may be explained by 
inhomogenieties in the uptake of the 18F-BPA.  This is not an unexpected finding in the 
postsurgical tumor bed in the peritumor regions with small clusters of cells and ITCs.  
Figure I.4 depicts the 18F-BPA distribution in the same plane through the brain (slightly 
rotated).  The distribution is clearly inhomogeneous in the remaining tumor bed and the 
peritumor region.  It is clear that there is a high probability that the center of the tumor 
will be totally obliterated by BNCT but cells only small distances away from the center 
of the tumor will receive a significantly less dose.  These findings explain the observed 
lack of local control and local recurrence of the glioblastoma multiforme.177, 178  
Evaluation PET scans on patients from UT Medical Center treated with BNCT often 
indicate the area of recurrence.178  In all cases, PET based dosimetry demonstrated a 
superior predictive value over the conventional treatment planning.177, 178 
 Though, PET based dosimetry is becoming widely used in BNCT treatment 
planning94, 107, 178-182 there are still some issues that have yet to be resolved.  The 
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Figure I.2  Pre-operative 18F-BPA-fructose PET scans of the same patient as in Fig. I.1 





Figure I.3  Treatment plan generated by SERA using 18F-BPA PET scan information. 
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Figure I.4  Two-dimensional activity plot showing inhomogenieties in the region of the 
glioblastoma multiforme. 
 
18F-BPA 3-D Activity Plot 
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pharmacokinetics of 18F-BPA PET scans have been reported183, 184 but the issue of scaling 
the dose has not been verified.  The patient receives approximately 10 mCi of activity 
(~10 ml) for an 18F-BPA PET scan.  This is in contrast to 1-2 liters of infusate (containing 
2-3 g of BPA) that is given to the patient prior to BNCT.54  The problem is currently 
solved mathematically using a convolution integral technique to scale the results to that 
which would be seen with the larger amount.  However, at this time, the approach has not 
been verified with clinical studies to show that these are equivalent, i.e., that the 
convolution interval in a PET scan recreates what happens in the patient given several 
grams in 1-2 liters of infusate of 18F-BPA.185-187 
 Most remarkable are the results from a patient with metastatic malignant 
melanoma a seen in Figure I.5.  Unlike glioblastoma, the distribution of BPA inside the 
tumor is much more homogeneous.  The 90% isodose curve is along the edge of the 
tumor with close spacing so that most of the dose is near and in the tumor.  In this case, 
only the tumor and neighboring cells would be expected to be killed by BNCT, which is 
unlike the case for glioblastoma.  Since malignant melanomas tend to expand in a more 
or less spherical manner, what appears on the scans to be tumor is most likely the extent 
of the tumor.  That is in contrast to the glioblastoma where its infiltrative nature means 
that there are small clumps and single cells far removed from the tumor itself.  Therefore, 
one would expect that malignant melanoma would be entirely destroyed by BNCT 
whereas glioblastoma multiforme would not.  These findings correlate well with results 
from the clinical trials to date. 
 
18F-BPA PET scanning provides an important addition to the treatment planning 
for BNCT.  Unfortunately, it is difficult to make 18F-BPA so that not all BNCT treatment 
planning is being performed with 18F-BPA PET scan data.  However, as PET centers 
proliferate, the use of a 18F-BPA PET scan to provide the boron-10 distributions is 
becoming the standard for treatment planning for BNCT. 
 
E. Statement of the Problem 
 
 One of the important clinical issues facing BNCT is to better understand the 




Figure I.5  18F-BPA PET scan of a metastatic focus of malignant melanoma.  The left 
hand frame shows a typical BNCT treatment plan with SERA while the right hand frame 
uses the PET data. 
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early impressive results with solid malignancies such as metastases from adenocarcinoma 
of the colon and malignant melanoma.  The treatment plans based upon 18F-BPA PET 
scans when compared to traditional treatment plans provide a macroscopic explanation 
but the basic idea of BNCT is that boron-10 laden tumor cells will be preferentially 
destroyed as long as those cells are in the neutron beam.  The ITCs in the periphery of 
glioblastomae are the apparent source of the local failure for this tumor.  The radiation 
milieu for these cells as compared to cells on the edge of a solid tumor such as melanoma 
should provide the explanation.  The local radiation milieu for ITCs will be determined 
by the neutron beam characteristics that then determine the nuclear reactions and 
scattering reactions.  The boron-10 reactions provide the largest component of the dose as 
will be shown.  The microscopic boron-10 distribution will determine most of the effects 
upon cells along the tumor periphery.  The geometrical arrangement of boron-10 laden 
cells should affect the dose to ITCs.  The near neighbor cells are postulated to increase 
the dose to non-boron-10 laden cells.  The effects of boron-10 concentration and cell 
geometries will be examined to explain the clinical observations in BNCT clinical trials. 
 30
II. Microdosimetric Models 
 
A. Basics of microdosimetry 
 
1. Concepts of microdosimetry for BNCT 
  “Microdosimetry is the area of study that deals with the microscopic distribution 
of energy in small volumes of matter by ionizing radiation”.188  In the ‘60s, ‘70s, and 
‘80s, Rossi and Zaider pioneered microdosimetry189-198 culminating in a textbook 
published in 1996.198  In their studies, Zaider and Rossi began to understand concepts of 
energy deposition in cells and the mechanisms of cellular damage.198  For human cancer 
therapy, there are three important aspects of micro-dosimetry: the physical distribution of 
absorbed energy (dose) into a small volume (on the order of microns) of tissue, the 
relative biological effectiveness (RBE) of the delivered dose, and the process that 
ionizing radiation leads to cellular demise. 
 Turning first to the physical energy distribution of energy deposited in a tissue, it 
is important to examine the spatial energy distribution for a given ionizing radiation.  The 
energy deposited in a tissue depends upon the kinetic energy, charge state, and mass of 
the ion.  The majority of interactions for an ion are electromagnetic scattering from 
electrons in the outer orbitals of molecules in the target.  The cross section for nuclear 
scattering of ions with appropriate radiotherapy energies and masses is low.188, 198  Ions 
possessing larger charge states will have stronger interactions with the orbital electrons, 
which results in a greater deceleration than lesser charge states.  Ions that are energetic 
and heavier (i.e. possess more linear momentum) tend to penetrate more and undergo less 
deflection from the orbital electrons.  The differences in ion tracks are demonstrated in 
Figure II.1 where an alpha particle, electrons generated by a photon, and 125I which has 
two-step nuclear decay: 125I (Electron Capture) → 125mTe (Isomeric Transition) → 125Te 
where the first step involves emission of K x-rays and Auger electrons.  The 5.4MeV 
alpha particle is seen to have a linear path and to produce electrons by scattering from the 
outer orbitals.  This is contrasted to the electrons produced by Compton scattering by 1.5 
keV X-ray photons where the electrons have complicated tracks from scattering from 
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other electrons.  The higher energy Auger electrons produced in the decay of 125I initially 
have straighter tracks but soon slow down and display many more scattering interactions.  
Thus, heavy, energetic, highly charged ions tend to travel in a more linear manner 
producing scattered electrons along the path of the ion.  
 As particles slow down along the track, the ion will have a peak in energy 
deposition near the end of the track and will travel a short distances seen in Figure II.2.  
In three dimensions, the energy deposition will resemble a teardrop and will generate free 
radicals in the same teardrop distribution.  As the ion slows, the track will become less 
linear because the interaction time with a given electron orbital increases, allowing a 
greater time for the electromagnetic interaction to alter the path.  Despite the alterations 
in the track and the distinctly non-linear energy deposition along the track as depicted in 
Figure II.2, most microdosimetry utilizes a linear stopping power approximation.  The 
stopping power is approximated by a straight line beginning at the initial ion energy at a 
displacement of zero and ending at an energy of zero at the maximum range.  Obviously, 
the range is a statistical value rather than a definite value but in microdosimetry it is 
usually taken as a definite value.  In this work, a linear stopping power is not employed 
but the range is taken as a fixed value.  Instead of a linear stopping power approximation, 
the stopping power curves are integrated along the required portion of the track. 
 The dose is defined by the amount of energy deposited in a region per unit mass 
with units of Gray (1 Gray = 1 J/kg).  The dose to a tissue does not fully describe the 
effect on a given tissue.  The kind of ionizing particle depositing the energy affects the 
damage to a tissue.  It is important to note that all radiation therapies rely on charged 
particle formation to damage cellular apparatus.  As an example, traditional photon 
therapy creates charged particles by Compton scattering of electrons in outer electron 
orbitals.  These electrons produce free radicals along their tracks, which damage nearby 
molecules.  However, some ionizing particles cause more biological damage than do 
other kinds.  In particular, high LET radiation causes greater biological damage than do 
photons.  To adjust for these differences the concept of relative biological effectiveness 






Figure II.1  Ionizations and excitations along particle tracks in water, for a 5.4 MeV α-
particle (top left), for electrons generated following the absorption of a 1.5 keV X-ray 
photon (top right) and electrons generated during the decay of iodine-125.199 
 
 
Figure II.2  The stopping power for 5.49 MeV alpha particles in air demonstrating the 
Bragg peak near the end of the track where much of the energy is deposited.  The image 
is courtesy of Helmut Paul. 
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where DX is the dose produced by a standard X-ray (often a 250 keV x-ray).  A typical set 
of RBE values is provided in Table II.1.  The neutrons in Table II.1 are fission spectrum 
neutrons, which are different from the epithermal beams used in BNCT.  The BNCT 
doses are often expressed as gray-equivalent (Gy-Eq), which is the sum of the various 
physical dose components multiplied to appropriate biologic effectiveness factors.  The 
BNCT literature contains a great deal of debate as to what values should be assigned to 
RBEs.  In this dissertation, the boron (n,α) and nitrogen (n,p) reactions are the only ones 
considered for reasons to be presented later.  For clarity, the results are presented in Gray 
rather than Gray-Equivalent. 
 Lastly, the radiation dose in radiotherapy is designed to destroy the malignant cell 
and to spare normal cells.  In general, it is felt that destroying the cell’s DNA is the way 
to destroy a cell.  The dosing is designed to deliver a smaller dose to normal cells and 
concentrate the dose into tumors.  The methods of doing this usually have to do with 
using multiple directions of a photon beam or placing a radiation source directly into a 
tumor (which in a sense is what occurs in BNCT).  The charged particles from radiation 
therapy directly deposit energy through electromagnetic interactions as the cellular 
constituents slow down the charged particle forming free radicals.  The charged particles 
can hit large molecules, such as DNA, directly which will cleave chemical bonds.  
However, more damage is probably done to the cell and its constituents by the effects of 
the free radicals.200-202  Free radicals can cleave bonds damaging nearby proteins, RNA, 
and DNA.  Since the number of free radicals formed is much greater than the single 
charged particle, more damage is done.  Heavy ions (in a biological sense an alpha or 
 




β particles 1 
α particles 10 to 20 
protons 1.1 
Neutrons:  Immediate radiation injury 1 
Neutrons:  Cataracts, Leukemia, and Genetic changes 4 to 10 
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heavier) can do significant damage.  As a high LET radiation, heavy ions will cause 
single and double strand breaks in DNA.  Double strand breaks are more difficult for the 
cell to repair than single strand breaks or single base deletions.  The DNA damage from 
heavy ion generated free radicals is usually less than the damage from heavy ions hitting 
DNA molecules.  Since free radicals diffuse away from the original sites, free radicals 
increase the likelihood for DNA damage.  Therefore, a heavy charged particle moving 
energetically past DNA may cause significant damage to the DNA without ever striking 
it due to free radical generation. 
 It is important to understand that the accepted method for cellular demise is from 
DNA damage.  The DNA damage can result in either apoptosis or relatively more rapid 
cellular demise.203  The apoptosis, i.e. programmed cell death, means that the natural life 
expectancy of the cell has been ‘reprogrammed’ to an earlier time.  When examined 
microscopically, these cells have no noticeable DNA damage.  Other cells are seen to 
have microscopically evident DNA malformations.203  The DNA malformations can 
result in two lethal outcomes.  First, the cell may not be able to perform mitosis 
successfully leading to cell death at that time.  The other result may be the loss of the 
ability to make a particular protein or proteins.  If those protein(s) are essential in the 
maintenance of homeostasis, the cell will die when the protein(s) are degraded through 
normal processes.  This mode of death can occur in a few days.  Finally, radiation therapy 
can cause immediate cell death that does not involve the above processes as is seen from 
blood samples immediately after a radiation treatment.204  The source of this immediate 
cell death is being studied with ion microbeams.  In some circumstances, neighboring 
cells (termed bystanders) provide protection to irradiated cells.  The opposite effect is 
seen as well where a cell damaged by radiation causes damage to bystander cells through 
a non-humoral mechanism.205-218 
Knowledge gained in the study of microdosimetry has helped to explain the 
oxygen effect that was already known to radiation oncologists.  Increased oxygen 
concentration intensifies the damage from radiation.  Intuitively, this is not expected 
since oxygen deprivation may be expected to cause more damage than an oxygen-rich 
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environment.  However, free radical formation is enhanced in high oxygen concentration 
and diminished in situations when the oxygen concentration is low.  The understanding of 
the microdosimetry of BNCT will be shown to be necessary to understand the clinical 
implications of BNCT. 
 
2. Stopping powers 
 Interest in the theory of energetic ions interacting with matter and slowing down 
dates back to Marie Curie’s work in 1898-1899 on radioactivity.219  Niels Bohr was the 
first to provide a theory of stopping powers220, 221 after the experimental work of Geiger 
and Marsden222 and the theoretical explanation of their work by Rutherford.223  Bohr’s 
treatment did not take into account quantum effects.  The first to include quantum effects 
was Bethe.224, 225  Bethe’s work was later refined by Bloch.226, 227  Stopping powers are 
expressed now by the Bethe-Bloch equation as refined by Fano.228  The history of 
determination of stopping powers is well reviewed by Ziegler.229  The major contribution 
to the stopping power for ions is due to the electromagnetic interaction between the target 
electrons and the positively charged ion.  The stopping power, S, may be written as: 
(II.A.2) 2 22 1 0 1 1 2 22 [ ( ) ( ( ...]
ZdES Z L Z L Z L
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(II.A.8) electron massem = , 
(II.A.9) speed of lightc = , 
(II.A.10) ion velocityv = , 
and 
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where L0 is the stopping number that contains corrections to the stopping power.  The 
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where C/Z2 is the shell correction for the target atom, <I> is the mean ionization energy 
of the target atom, and δ/2 is the density correction.  The largest possible energy loss in a 
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where M1 is the mass of the ion.  The shell correction term takes into account the 
assumption that the ion velocity is much larger than the target electron velocity.  The 
calculation requires careful accounting of the ion with the electrons in the various 
electron shells in the target.  The mean ionization corrects for the quantum mechanical 
energy levels that target electrons have available for transfer.  Finally, the density term 
corrects for polarization effects in the target. 
 The L1 term in equation (II.A.11) is called the Barkas correction after the work by 
Barkas et. al.230 and the L2 term is the Bloch term.  These terms deal primarily with two 
experimental observations.  The first is that two ions of the same mass and velocity in the 
same target have different ranges where the only difference is for different sign of the ion 
charge.  The other effect is the corrections required for the magnitude of the charge.  For 
example, according to the basic Bethe-Bloch equation, an ion with charge +2 should have 
four times the stopping of a similar particle of charge +1 but experimentally the stopping 
exceeds a factor of four. 
 The greatest interest in the calculation of stopping powers has traditionally been 
focused on high energy ions rather then the low energy ions used in BNCT.  The standard 
for the BNCT field, as well as many other fields for calculating stopping powers is a 
program that was developed by Ziegler231, 232 (originally in FORTRAN) several decades 
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ago that has been refined and improved over the years.  The program is now called 
SRIM2008 (Stopping Range In Matter), which is available, online at www.srim.org.  The 
program uses the basic Bethe theorem of charged particles stopping with Bloch shell, and 
Barkas corrections to generate a theoretical curve that is then compared to and matched 
with experimental data.  The results provide accurate (1 to 2%) results for high energy 
ions, > 5 MeV/amu, but can be off as much as 20% for low energy ions, < 1 MeV/amu, 
because at low energies the ions will travel distances on the order of Ångstroms (see 
details at www.srim.org).  The calculation of stopping powers also requires the use of an 
approximation termed the continuous slowing down approximation (CSDA).  The actual 
path of an ion involves quantum mechanical interactions with molecular electron orbitals.  
The ion slow down is not smooth and continuous but has discrete interactions (though the 
range is large since they are electromagnetic in nature).  The details for this calculation 
are difficult to obtain so the CSDA is used where there is little data.  The program also 
allows for the selection of a number of compound targets including tissues based upon 
the additivity of stopping powers.  Type II breast tissue was used in these calculations 
since it best emulated brain tissue and there are no brain tissue options in the targets.  The 
calculations of the stopping powers for the proton from the 14N(n,p)14C reaction as well 
as the alpha particle and the lithium nucleus from the 10B(n,α)7Li reaction for this work 
were performed with SRIM2008.  The range for the five ions is shown in Table II.2 
where it is noted that the lithium ions have very short ranges.  The maximum range for 
these ions is that of the proton which is still only 10.52 µm.  The proton range is on the 
order of one cell diameter so none of the ions will affect cells more than one or two cells 
removed from the site of the reaction.  This emphasizes that the radiation is very focused 
wherever the reactions occur.  Figure II.3 contains the stopping power plot for the proton 
from the 14N(n,p)14C reaction showing the Bragg peak that occurs near the end of a 








where dx is along the particle track.  The stopping power for the other ions are similar but 
start closer to their Bragg peak as is seen for the 1,780 keV alpha particle from the  
 38
Table II.2  Range of BNCT associated ions in human tissue. 
Ion Atomic Number Atomic Mass Initial Energy (keV) Range (µm) 
H 1 1.008 590 10.52 
He γ 2 4.003 1470 7.39 
He 2 4.003 1780 9.06 
Li γ 3 7.016 840 3.93 
Li 3 7.016 1010 4.38 
  
 
Proton stopping power for the 14N(n,p)14C reaction
Range (µm)




















Figure II.3  The proton stopping power for the 14N(n,p)14C reaction showing the energy 
deposition per unit length as a function of the remaining range.  The peak is known as the 
Bragg peak and is near the terminus of stopping powers for all energetic ions where there 





10B(n,α)7Li reaction in Figure II.4.  It should be noted that most authors in BNCT employ 
a linear slowing approximation where the ion is considered to slow down from the initial 
energy to zero linearly over the range of the ion not taking into account the actual 
stopping power utilizing SRIM2008 only to find the ion range.  The present work uses 
the actual stopping power rather than a linear stopping. 
 
3. Determination of the number of interactions 
It is important to consider the number of 10B(n,α)7Li interactions that occur in a 
given volume of tissue.  The number of interactions, ni, can be determined by: 
  
(II.A.15) 




3840 barns 10 cm 4x10 neutron 50 µg 10 g
* * * * *
B atom barn cm g µg
6.023x10 atoms 1 mole 1g 10 ml interactions
     * * *  = 0.46 
1 mole 10 g ml µm µm
I =
 
where the commonly accepted neutron fluence is 4 x 1013 n/cm2, the boron thermal 
neutron cross section is 3840 b/atom, the density of tissue is ~1 g/ml, and the boron 
concentration is taken to be 50 µg/g (= 50 ppm).  Thus, there is actually few 10B(n,α)7Li 
interactions in any given volume of boron concentration 50 ppm.  The value of 50 ppm is 
an accepted value for the cellular boron concentration with the interstitial space and 
normal tissue having a concentration of 10 ppm.114, 115, 117  The model herein uses 
ellipsoids arranged in a body centered cubic.  So for example, consider a cell of radius 
5.0 µm with a concentric nucleus of 4.0 µm in a body centered cubic structure (as are all 
geometries herein) so that the cells are touching (i.e. a separation of 0 µm).  The sides of 
the region of interest are taken so that the entire cells lie within the boundaries of the 
region of interest.  In that case, the sides for 5 x 5 x 5 cells in a body centered cubic are 
55 µm x 55 µm x 38.28 µm for a total volume of 115,797 µm3 with a cellular volume of  
(II.A.16) 3 3
 
4125 65, 449.85 µm
3Total Cells
V rpi = = 
 
. 
So that the total number of boron interactions will be: 
(II.A.17) ( ) ( )0.460.46 65, 450 115,797 65,450 34,738 interactions
5
I = + − =  
 40
Alpha particle stopping power for the 10B(n,α)7Li reaction
Range (µm)




















Figure II.4  The alpha particle stopping power for the 10B(n,α)7Li reaction showing the 
energy deposition per unit length as a function of the remaining range.  The alpha track is 
seen to start near to the Bragg peak. 
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for the entire volume.  Newer boron carriers121 promise better tumor concentration of the 
order of 20:1 which would give for the same example a total of 125,060 interactions with 
the increase of 90,322 interactions all occurring in the tumor cells.  The linear nature of 
number of interactions in tumor cells emphasizes the importance of developing more 
tumor specific boron carrier molecules. 
 
B. Review of prior models of BNCT microdosimetry. 
 
 The microdosimetry of BNCT has been approached by two techniques.  One 
approach is to construct a very structured regular three dimensional array of cells and the 
corresponding nuclei and distribute boron within that system.  This approach can be best 
seen in the work of Hartman233, 234 and Carlsson235 who developed a cubic structure to 
model the cells with a spherical centered nucleus.  The other approach to the problem has 
been to model a single cell with a very large interstitial volume.  The best illustrations of 
this technique are by Charlton,236-238 a group at Petten,239-242 and a group at 
Harvard/MIT.243-245 
 The reason for the two approaches noted above is the difficulty of following 
particle tracks in complex geometries.  The single cell code allows for ellipsoidal cells 
and ellipsoidal nuclei.  Therefore, if the cells (i.e. cytoplasm and nuclei) contain most of 
the boron, their arrangement in proximity to one another can influence the dose on each.  
Actual cells are stacked very close to one another with about 15% of the volume of a 
cube of brain tissue being interstitial fluid, the rest being intracellular.  The nuclei tend to 
be eccentric and are spheroidal.  The cells are not spheres or ellipsoids though for some 
cell types these are reasonable approximations.  Tumors are often pallisading.  Even in 
highly organized tissues such as those found in the kidney and the liver, the computer 
models are more organized than the tissues.  These two approaches use Monte Carlo 
techniques to generate the tracks and interactions.  The dose components that are 
calculated determine only the doses due to the boron (n,α) reaction and the nitrogen (n,p) 
reactions.  These reactions account for ~70% of the total dose delivered to the tissues if 
the boron concentration in the tumor is 50 ppm.91  Hartman and Carlsson noted that 
membrane-bound boron could add a non-negligible dose component to each cell.235  They 
 42
also determined that boron needs to be present in the cytoplasm and nucleus of most 
every cell in order to have sufficient dose to kill the cells.  Charlton238  and Santa Cruz et. 
al. verified these findings.7  They demonstrated that boron attached to the surface of the 
cells, as with boronated antibodies, would not likely deliver sufficient nuclear dose to kill 
the cell.  Also, they showed that large interstitial boron concentrations would not provide 
nuclear dose sufficient to destroy the cell.  These authors have independently shown that 
most of the boron has to be concentrated in the cell cytoplasm and/or nucleus. 
 
C. Simulation implementation 
 
1. The Cells program 
Cells is a program designed to arrange the ellipsoids that represent cells in a body 
centered cubic.  The simulation programs (Cells, Dose, and Evaldose) were written in 
FORTRAN using the Fortran 95 Pro v5.7 compiler by Lahey Computer Systems, Inc.  
The program design is essentially linear where after the user inputs control parameters for 
the program, the code first uses well known relationships to determine the cell centers for 
the ellipsoids.  The nuclei are then determined based upon the user input parameters.  The 
results are then output for viewing and for input into Dose.  The program can loop over 
cell radii by setting an initial radius, an increment, and the number of loops.  The same 
thing can be done for the nuclear radius, the eccentricity, and the cell separation.  The 
eccentricity is taken by the common usage in nuclear physics that keeps a constant 
volume as the eccentricity varies.246  For an ellipsoid defined by the parametric equations: 
(II.A.18) 0cos sinx a xθ φ= +  
(II.A.19) 0sin siny b yθ φ= +  
(II.A.20) 0cosz c zφ= +  
where 
(II.A.21) ( ) ( ) ( )2 2 22 2 2 20 0 0r x x y y z z a b c= − + − + − = + + . 
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which clearly is independent of ε so that the volume of the ellipsoid remains constant for 
variable eccentricity. 
The nuclei can have the same ellipsoid shape as the cell or to remain a sphere that 
is closer to the in vivo situation.  The nuclei can be constrained to be concentric with the 
cell center or it can be non-concentric.  The non-concentric nucleus can be randomly 
determined for every cell for each loop or can be randomly determined for the first loop 
and same nuclear centers will be used for the remaining loops.  The randomness can be in 
the displacement from the center and two angles defining a unique direction defined by 
the user.  Alternatively, the displacement can be user defined and the displacement 
randomly determined.  Finally, the user can define a direction and displacement for the 
nuclei.  The program will not pick a nuclear center that will produce a nucleus that lies 
partly outside of the ellipsoidal cell but user defined nuclei are not checked.  Dose cannot 
correctly handle cells with nuclei that lie partly outside of the cell and will produce error 
messages. 
A few spherical cells are shown in Figure II.5 showing the body centered cubic 
configuration for spheres showing the cell placement.  This can be contrasted with cells 
of the same radius but with an eccentricity of 1.5 as defined in equations (II.A.22) and 
(II.A.23).  The cells lie side by side as the eccentricity increases which is seen in muscle 
and neural tissues among others as seen in Figure II.6. 
 
2. The Dose program 
 The Dose program calculates the energy deposited into the interstitium, 
cytoplasm, and the nuclei.  It should be pointed out that Dose outputs energy deposition 
rather than actual dose.  The next program, Evaldose, converts from energy deposited to 
actual dose by a multiplicative constant and the tissue density.  Dose requires the  
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Figure II.5  An example of a few cells with a radius of 5 µm, an eccentricity of 0, and a 




Figure II.6  A few cells with a radius of 5 µm, an eccentricity of 1.5, and a separation of 
1.0 µm whose positions were determined by Cells contrasting with spheres of the same 
radius. 
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ellipsoidal geometry output from Cells and certain user determined inputs.  The user 
determines whether the particular case is a validation run which only increases the 
amount of information that is output.  Other user input has to do with the method for 
maintaining charge, particle, energy, and momentum conservation.  One method involves 
a particle that departs the region of interest is replaced by another particle of equal 
charge, momentum, energy, etc entering on the opposite side at the same position on that 
side.  The other method involves picking a random side.  Both give good validations but 
the first method was used exclusively in this work.  The random position inside the 
region of interest can be designated as uniform throughout the volume or it can have a 
three dimensional Gaussian distribution with the peak centered in the geometric center of 
the region of interest.  The second method roughly emulates a capillary as a source of 
BPA.  The source in even a small space should be cylindrical so that this option was not 
used in the present work. 
 The program then asks whether the dose due to the 14N(n,p)14C is to be calculated.  
Next the user inputs the boron-10 concentration in parts per million for each of the three 
regions considered.  The last user input determines how the number of interactions is to 
be determined.  One option is to input the number of interactions in the total region of 
interest for each case.  The alternate option is to use equation (II.A.15) to determine 
automatically the number of interactions in the region of interest.  The first option is used 
for validation and statistical evaluations whereas all other cases allowed the program to 
determine the number of interactions. 
 The program then loops through the number of interactions that has been set.  The 
first part of each loop is to generate an (n, p) or (n,α) reaction based on the relative 
likelihood.  Then three random numbers are generated to determine a point in the region 
of interest.  After determining whether the point lies in the interstitium, cytoplasm, or a 
nucleus, a random number is generated to determine whether the point is to be accepted 
based on volume percent and boron concentration at the point.  If the point is rejected, 
another point is generated and the process repeated until there is a valid interaction.  By 
generating numbers in a unit cube rejecting all that lie outside of a unit sphere, random 
directions can be obtained to determine the direction of the first ion: a proton from the 
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(n,p) reaction and two pairs of ions from the (n,α) reaction with differing energies (if 
there is a γ-ray or not).  The alpha and lithium ion pairs are separated by pi radians.  Thus, 
a track or tracks are determined.  The track is then examined to see what boundary it 
crosses: the region of interest, the cell, or the nucleus.  The track is then broken into a 
first piece.  The same process is repeated until the entire ion track has been broken up. 
 Once the track has been broken into pieces, each piece is integrated with a Gauss 
quadrature code using the actual stopping power curve for that portion.  The actual 
stopping power curves are used rather than a linear stopping power in order to improve 
the accuracy of the results.  The energy deposited into the interstitium, a particular cell 
cytoplasm, or a particular cell nucleus is summed with previous contributions.  The 
process is repeated until all interactions have been calculated.  As with all codes, the 
program was written in double precision to achieve the best results. 
 
3. The Evaldose program 
 The program Evaldose is a post-processing program that takes the output data 
from Dose summing and arranging it into a tabular form rather than as separate data sets.  
It also converts from energy deposition to the dose using the average density of tissue 
taken as 0.99 g/ml3.  It requires no user supplied input and performs no calculation except 
for summing.  The first sums are to sum the doses for all cells, cytoplasm and nuclei 
independently, for a given geometry and boron distribution.  Then the total dose to all of 
the cells is determined as well as the total dose to the region of interest, i.e. the total of all 
of the cells and the interstitium for the region of interest.  The data set is then output to a 
file in a tabular form suitable for graphing. 
 
4. Mathematica and SigmaPlot programs 
 SigmaPlot 2000 for Windows version 6.00 is a program available from Systat 
Software, Inc., 1735 Technology Drive, Suite 430, San Jose, CA 95110.  It is designed 
for plotting data and fitting that data to various functions (both linear and non-linear) as 
well as performs basic statistical evaluations.  All of the data plots in chapter III were 
generated with SigmaPlot 2000 except for the plots of ellipsoidal cells.  The ellipsoidal 
cells were drawn with Mathematica 6.0.3.0, Wolfram Research, Inc., 100 Trade Center 
 47
Drive, Champaign, IL 61820-7237.  Mathematica is a powerful code designed for 
interactive mathematical programming to arbitrary accuracy.  It also possesses advanced 
graphics capabilities that were used to produce the plots of the ellipsoidal cells.  Neither 
of the codes was used for data generation or analysis with the exception of some 
statistical analysis of the dose results and some graphically displayed fitting to different 
functions. 
 
D. Program validation 
 
1. Validations 
 Examining the centers, radii, and eccentricity of the cells and nuclei easily 
validates the output from the Cells program.  Evaldose essentially sums the data from 
Dose so that it is validated by comparing the sums for small data sets to manually 
calculated sums for the same data sets.  Cells and Evaldose are essentially validated by 
inspection. 
 Validating a complex code such as Dose is much more involved.  As the code was 
developed, portions of the code were tested independently to assure proper functioning.  
When the code was completed, several tests were devised to assure that the program 
functioned correctly.  Dose tracks starting and ending track locations by two different 
particles that are output and are identical.  The whole region of interest (ROI) is a 
rectangular parallelepiped that encompasses the ellipsoidal cells in their entirety.  The 
requirements for validation are particle, energy, and momentum equilibrium.  These 
requirements have been met to statistical accuracy as is demonstrated for the case: cells 
of radius 6.0 µm having concentric nuclei of radius 4.0 µm both with eccentricity of 0 
and with the boron concentration of 50 ppm everywhere with both 10B(n,α)7Li and 
14N(n,p)14C calculated.  For this example, there are 13,077 boron interactions (6,539 
originating in the interstitium, 4,601 in the cytoplasm, and 1,937 in the nuclei) and 3,082 
nitrogen interactions for a total of 16,159 interactions in the volume.  The number of 
particles leaving the ROI is 4,642 which is the same as the number entering so that: 
(II.A.25) leaving enteringIons Ions= . 
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The ions have a charge of 2+ for alphas and 3+ for lithium so that for charges, q, and from 
the result of (II.A.25) charge equilibrium is preserved when 
(II.A.26) Li Li
in in out out
q q q qα α+ = +∑ ∑ ∑ ∑  
which is always satisfied.  The net momentum in the x, y, and z directions sum exactly to 
0 for each of the components so that the momentum vector has the value of 
(II.A.27) 0in outP P P= + =
  
. 
The total energy entering the rectangular parallelepiped is 8.289 x 105 J and the total 
energy leaving the region is 8.289 x 105 J so that: 
(II.A.28) 0in outE E E= + = . 
 For this case, the energy deposited in each of the three volumes (the nulcei, 
cytoplsm, and interstitium) should have the same proportion to the total energy deposited 
as that volume represents of the entire volume.  This is because the boron and nitrogen 
concentrations are the same everywhere.  Likewise, the dose should be the same 
everywhere so that it provides another validation to the code.  The data for this case are 
shown in Table II.3.  The agreement is quite good.  The program has met tests on 
components and has been validated.  Most of the above information is compiled on every 
run so that there are checks on every run for the dose program.  The programs written for 
the determination of the microdosimetry of BNCT have been validated. 
 
2. Comparisons to the results of other authors 
 Currently, the standard of comparison in the field of BNCT microdosimetry is the 
work of D. E. Charlton in 1991.238  In this work, the dose to a single spherical cell is 
calculated for two cases.  In both cases, the nitrogen dose was calculated for a 
concentration of 3.5 g/100g and the boron dose was calculated for a boron-10 
concentration 5 µg/g.  In the first case, the cell radius was 5 µm with a concentric nucleus 
of 2.5 µm while in the second case the cell radius was held constant and the concentric 




Table II.3  Energy deposition as a percent of the total energy deposited, dose, and 
percent volume of three volumes to the total. 
 Energy Deposition 
(% of total) 
Volume 
(% of total) 
Dose (Gy) 
Interstitium 50.31 50.00 22.81 
Cytoplasm 34.93 35.18 22.51 




Table II.4  The nuclear dose from the work of Charlton and from the program 
Dose. 
Nuclear Size (µm) Charlton dose (Gy) Dose (Gy) 
2.5 3.51 3.46 
3.5 3.55 3.56 
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III. Results and Discussion 
 
A. Characteristics of the neutron beams for BNCT 
 
Despite considerable effort to achieve an accelerator based neutron beam 
source,247-256 accelerator derived epithermal neutron beams have yet to be able to deliver 
a sufficient flux of neutrons to perform BNCT in a reasonable time for a patient to be 
relatively motionless without sedation (on the order of a few tens of minutes).  So to date 
all human and most animal studies have been performed with reactor based neutron 
sources.  Since BNCT is dependent on the large absorption cross section of 10B for 
thermal neutrons, i.e. neutrons with energies < 1 eV but with most being ~0.025 eV 
which is a mode of the Maxwell–Boltzmann distribution, it is necessary for the neutron 
energies to be in the thermal range at the depth of the tumor.  Most tumors of interest do 
not occur on the surface of the body so that techniques have been developed during the 
early years of BNCT to deal with deep-seated tumors such as GBM.  In Japan, 
Hatanaka38 approached the problem by using a thermal beam from a power reactor and 
reflected (removed a piece of the skull and placed it back in place after the surgery) the 
skull for the irradiation.  However, the Japanese have largely abandoned this approach in 
favor of using an epithermal neutron beam.181, 257 
In the United States, epithermal neutron beams were developed at the MIT reactor 
(MITR) and the Brookhaven Medical Research Reactor (BMRR) so that the neutrons 
would be sufficiently energetic to penetrate a few centimeters of tissues before slowing to 
thermal energies.  Binns, Riley, and Harling87 compared the characteristics of seven 
different neutron beans for BNCT reporting air epithermal neutron flux ranges 0.2 to 4.3 
x 109 n cm-2 s-2.  Figure III.1 contains a summary of the thermal neutron flux as a 
function of depth in an ellipsoidal water phantom using gold foil activation analysis.  The 
peak occurs around 2-4 cm in depth for the beams studied with a fall off of 50% at 
approximately 6 cm.  The thermal neutron flux maxima used in producing Figure III.1 are 
given in Table III.1 for the seven beams that were studied.87  The distance traveled in 




Figure III.1  Thermal neutron (~0.025 eV corresponds to a neutron velocity of ~2200 m 
s−1) flux obtained from the analysis of gold foil activation at seven different clinical NCT 
facilities in Europe and the U.S.  Measurements were performed in an ellipsoidal water 
phantom under conditions pertinent to clinical irradiations.  The results for each beam are 
normalized to the measured maximum shown in Table III.1 and have an estimated 
uncertainty of 4.4% at shallow depths increasing to 6.0% at 10 cm.87 
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Table III.1  Measured maxima for thermal neutron flux as well as photon and fast-
neutron absorbed dose rates at the seven different NCT facilities in the U.S. and 
Europe.87 
In-phantom Maxima MIT FCBa Studsvikb FiR-1 BMRRc ReZ HFR MIT M67c 
f2200 (109 n cm-2 s-1) 5.70 2.68 1.95 1.48 1.18 0.72 0.20 
Photon dose rate  
(cGy min-1) 
31.0 18.1 9.8 6.3 9.5 5.0 2.6 
Fast-neutron dose rate 
(cGy min-1) 
3.2 4.3 2.3 1.6 6.7 1.6 1.7 
Note. These values are used to normalize the flux depth profile and depth-dose curves 
illustrated in Figs. 1-3. 
aFision converter operating at 83 kW. 
bBeam line configured with 9-mm-thick 6Li flter installed. 
cDecommissioned. 
 
interaction is an elastic scattering.  For low energy n-p reactions, the scattering is largely 
elastic which allows evaluation by a classically derived relation: 
(III.A.1) ( )1 1 cos
2p n
E E φ= −  
where φ is the center of mass scattering angle, En is the energy of the incident neutron, Ep 
is the energy of the recoil proton, and the mass of the proton and neutron are taken to be 
equal which is sufficient for the estimation here.  This means that, on average for elastic 
scattering, the neutron losses ½ of its kinetic energy in each collision with the proton in a 
hydrogen atom so that: 
(III.A.2) 1
2p n
E E= . 
So, for an initial neutron energy of Ei that undergoes n collisions, the final average 
energy, Ef, is approximated by: 
(III.A.3) ( )12 ni fE E=  
or solving for n: 
(III.A.4) ( )1 12 f iEn Ln Ln E−  =     
So for a maximal epithermal neutron of initial energy Ei = 10 keV being thermalized to a 
final energy of Ef = 0.025 eV, n10 keV = 18.6 or ~19 collisions.  Compared to n1 eV ∼5 
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collisions for neutrons with an initial energy of 1 eV.  The mean free path of a neutron 
may be approximated from the elastic cross section, σi, and the number densities, Ni, of 











Table III.2 contains a typical elemental abundance of light elements along with the 
corresponding number densities, elastic scattering cross sections, number density-elastic 
cross section products.  Using equation (III.A.5), the thermal neutron mean free path is: 
(III.A.6) 0.46 cmthermalλ =  
Using the same calculations, Table III.3 contains the mean free path as a function of 
epithermal neutron energy.  Using a typical value for the mean free path of 0.67 cm and 
19 collisions, an epithermal neutron with an initial energy of 10 keV will travel 12.7 cm 
prior to reaching a thermal energy, while a neutron with an energy of 1 eV will travel 
~3.4 cm until the neutrons are thermalized.  The neutrons scatter in random directions; 
the total distance traveled is not a straight line.  So most of the epithermal neutron flux 
has thermalized by a depth in a phantom of ~10 cm as inferred from Figure III.1.  At 
typical tumor depths of a few centimeters, much of the neutron beam will be thermalized.  
Also, the multiple scattering reactions result in neutrons having momenta vectors with 
random directions especially on the scale of microdosimetry calculations (<~150 µm).  
The important implication for the microdosimetry of BNCT is that, except for superficial  
 
Table III.2  Typical tissue elemental abundance, number density, and elastic 







σ (b) Nσ(cm-1) 
H 0.11   1.008 6.51E+22       30.39        1.977084 
C 0.51 12.010 2.53E+22 4.746 0.120158 
N 0.02 14.010 8.51E+20       12.19 0.010372 
O 0.36 16.000 1.34E+22         3.97 0.053320 
Na   0.001 22.990 2.59E+19         3.92 0.000102 
P   0.001 30.970 1.92E+19         4.37 0.000084 
S   0.001 32.070 1.86E+19         1.52 0.000028 
Cl   0.001 35.450 1.68E+19       65.32 0.001099 
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Table III.3  Mean free path, λ, for different epithermal neutron energies. 
Ei (eV) Nσ(cm-1) λ(cm) 
1 1.5131 0.66091 
10 1.4939 0.66937 
100 1.4919 0.67031 
1000 1.4846 0.67356 
10000 1.4277 0.70043 
 
tumors, there is no preferred direction for the thermal neutrons making the probability of  
a 10B(n,p)7Li reaction dependent only upon the distribution of 10B in the region of 
interest. 
 The beams from the reactors are collimated and provide a relatively flat 
distribution of neutron energies.  For example, the Washington State University reactor 
has a flat distribution curve within a factor of about 2 for the epithermal neutron energies 
from ~0.414 eV to ~10 keV and produces a measured epithermal neutron flux of 4.94 x 
108 n/cm2-sec while operating at 1 MW as shown in Figure III.2.  This distribution allows 
for the most flexibility in treatment planning so that the lower energy neutrons are 
thermalized in the first 1-2 cm while the higher energy neutrons are not completely 
thermalized until ~10 cm into the phantom as shown in Figure III.1.  The peak number of 
thermal neutrons, as shown in Figure III.1, occurs in the 2-4 cm range and slowly tails off 
which dictates that most of the tumor region should be within ~6 cm of the body surface.  
Large or deep tumors are not going to be as amenable to treatment due to a lack of 
thermal neutron flux without prolonged irradiation times and increased damage to 
surrounding normal tissues. 
Fast neutron contamination of the epithermal beam is a potential source of dose in 
the microscopic region of interest.  One of the common components of the beam filters 
for BNCT is Al2O3 that decreases the fast neutron flux while allowing epithermal 
neutrons.  Using Equation (III.A.5) and cross sections for a reactor produced fast neutron 
of 1 MeV, the fast neutron mean free path is λfn = ~2.4 cm.  Following the same 




Figure III.2  The unfolded free beam neutron spectrum of the Washington State 
University reactor at 1 MW power in the source plane obtained by direct fitting.  The 
spectrum demonstrates a relatively flat distribution of epithermal neutron energies within 
a factor of ~2.263 
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after undergoing some 25 collisions and depositing the 1 MeV of energy.  The reactor 
neutron beam filters are carefully designed to minimize the fast neutron flux that actually 
reaches the patient.  For example, the reactors that were used in the US clinical trials had 
dose rates of 1.7 and 1.6 cGy sec-1 for the Brookhaven and MIT reactors respectively.87  
For typical treatment times of 45 minutes, the patient receives a total fast neutron dose of 
~0.75 Gy.  The new fission converter beam at MIT has a larger dose rate of 3.6 cGy sec-1 
but the treatment time is only ~10 minutes so that the total neutron dose is 0.36 Gy which 
is about half of the above dose.  Another way to examine the problem is from the fast 
neutron flux.  The fast neutron flux from the Taiwan THOR reactor is 7.66 x 106 n/(cm2 
sec) while the fast neutron flux from the EU HFR reactor is 2.61 x 106 n/(cm2 sec).  As 
was done before, the dose may be approximated for this case by: 
(III.A.7) fn fn fn fnD E I E Nφσ= = . 
So for a 1 MeV fast neutron, the dose may be written as: 
(III.A.8) ( ) ( )
( )
13 22 24 2
3
14
 1.0622 10 6.51x10 4.246 10
     4.429 10 /
fn












where the fluence, φ, is determined by multiplying the flux by the treatment time.  Using 
a typical treatment time of 45 minutes and remembering that the density of the brain is 
~0.99 mg/cm3 = 0.99 kg/m3, the fast neutron dose at THOR is 0.092 cGy and HFR is 
0.031 cGy.  Thus, fast neutrons are capable of contributing a significant dose via recoil 
protons but the small fluxes prevent them from playing an important role. 
 
B. Contributions to the microscopic dose 
 
The radiation milieu in BNCT is complicated by neutron interactions in tissue and 
from radiation from the reactor ‘contaminating’ the neutron beam.80, 239, 258-262  The beams 
have different filters to produce a neutron beam with a relatively flat energy distribution 
in the epithermal range as discussed above in section A.  The characteristics of the  
radiation is dependent upon the particular beam which is a function of the reactor and 
filters.87  Most beams have some γ-ray contamination but the intensity and energy 
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spectrum is dependent on the details of the particular reactor and beam.  These  
contaminants to the epithermal beam will not be considered because it is installation 
dependent. 
The major sources of the radiation dose from the neutron interactions with tissue 
do need to be considered.  The most important are the reaction products from the 10B 
reaction, i.e. the alpha particles, the lithium nuclei, and the γ-ray.  Additional components 
in the radiation milieu are the proton produced in the nitrogen (n,p) reaction.  Recoil 
protons produced when neutrons elastically scatter from hydrogen atoms attached to 
organic molecules will also be considered.  Also, hydrogen has a non-negligible cross 
section for neutron capture that results in deuterium and a γ-ray.  Since hydrogen is in all 
organic molecules, this contribution to the dose will also be considered.  The cross 
sections for other reactions or the number density are so small that other reactions will 
not be considered.58, 262, 264, 265 
 
1. The contribution from the 10B(n,α)7Li and 10B(n,α γ)7Li reactions to 
the dose 
The major dose components in BNCT derive from the 10B reaction itself so a 
discussion of the radiation components making up the total dose will begin with the 
BNCT reaction.  As discussed in chapter II, the characteristics of energy deposition in the 
region of interest determine the microscopic dose.  BNCT has many potential sources of 
energy deposition and so the dose calculation for the macroscopic dose is complex.  
Barth, Soloway, et. al. report that if the tumor boron concentration is 20-40 micrograms 
per gram (109 10B atoms/cell) then 75-80% of the radiation dose arises from the 
10B(n,α)7Li and 10B(n,α γ)7Li reactions.90  Along with the proton dose are other reactions 
such as the recoil reaction of the proton in hydrogen from the incident neutrons and the γ-
ray from the 10B reaction, which provide the remainder of the dose from reactions other 
than the 10B reaction.  The dose from the γ-ray produced in the 10B(n,α γ)7Li reaction will 
be considered in section III.B.3.  Some of the components, which are important in 
calculating the macroscopic dose, are of a lesser significance to the understanding of the 
microscopic dose due to magnitude and lack of significant spatial variation on a 
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microscopic basis.  To understand the microdosimetry of BNCT, it is instructive to begin 
with the ions produced in the BNCT reactions: 
(III.A.9) 93.7%1 10 11 * 7 40 5 5 3 2n+ B B Li+ He+γ(0.48 MeV)+2.31 MeV→ →  
and 
(III.A.10) 6.3%1 10 11 * 7 40 5 5 3 2n+ B B Li+ He+2.79 MeV→ → . 
The heavy ions produced are charged to the 2+ state for the alpha particle and 3+ state for 
the lithium nucleus.  These highly charged ions have relatively short ranges in matter.  
The high charge states interact with the electron clouds and the nuclei by Coulomb 
interactions quickly slowing down and depositing all the energy from the disintegration 
of the metastable 11B that decays immediately (t1/2~10-12s).266  The short ranges of the 
ions from BNCT are shown in Table II.2 that was generated by the SRIM2008 code 
discussed in chapter II.  The short ranges are beneficial because the ions travel on the 
order of a cell diameter (which varies depending on the cell type but generally is about 10 
µm) depositing their entire energy.  Thus, a cell may have the entire energy from the 
10B(n,α)7Li reaction (an average of 2.34 MeV) deposited within the cell.  The Coulomb 
interactions with the molecules along the path of the ions results in the production of 
short lived free radicals which then significantly damage nearby molecules as discussed 
chapter II.A.1.  Any ion paths through the cell’s nucleus can result in major damage to 
the DNA from two mechanisms.  The first is from direct damage by the heavy charged 
ions resulting in double strand DNA breaks which the cell is less able to repair than 
single strand breaks.  The second mechanism is from free radical formation, which also 
damages the DNA.  Traditional photon beam radiation damages cells by free radical 
formation so that the combination of the two is often lethal to the cell.  Thus, the 
effectiveness of BNCT is dependent upon the local boron concentration91 as will be 
shown.  Nearby normal cells or tumor cells in the G0 (resting) phase will not accumulate 
the boronated carrier molecule as avidly as tumor cells and will receive a smaller 
radiation dose than the active tumor cells where the boronated carrier molecule 
concentrates.  The 10B(n,α)7Li and 10B(n,α γ)7Li reactions are generally considered to 
responsible for about 80% of the total macroscopic dose with most of the variability due 
to the variation in boron concentration.91 
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2. The contribution of the 14N(n,p)14C dose 
 Nitrogen is a common element in all human tissues and the 14N(n,p)14C reaction 
can produce a significant dose in BNCT.  The nitrogen capture reaction may be 
summarized by: 
(III.A.11) 1 14 14 10 7 6 1n + N C + H + 0.59 MeV→ , 
which occurs in all tissues.  The proton deposits 0.59 MeV in a range of ~10.5 µm in 
human tissue as determined by SRIM2008.  The distribution of nitrogen is not entirely 
homogeneous for different cell types with the concentration being higher in protein rich 
as opposed to lipid laden tissues but the heterogeneity is small except for adipose tissue.  
Even adipose cells have typical cellular architecture with proteins, RNA, DNA and other 
nitrogen rich molecules.  The in vivo heterogeneity is not significant for most tissues and 
in particular for tumors that rarely have lipid laden cells (except for the rare liposarcoma).  
There are no studies describing the nitrogen distribution on a cellular or sub-cellular level 
and nitrogen is ubiquitous in all tissues so that it is not unreasonable to model the 
nitrogen distribution as homogeneous.  If the nitrogen distribution is homogeneous, the 
contribution to the total dose would be expected to be small and additive.  This may be 
shown by plotting the dose for spherical cells of radii rc = 4.0 µm with nuclei of radii rn = 
3.0 µm that are plotted as a function of the edge to edge separation of the cells in a body 
centered cubic.  The 10B concentrations being 10 ppm, 50 ppm, and 50 ppm in the 
interstitium, cytoplasm, and nuclei respectively, which is consistent with experimentally 
determined values.114, 115, 126  Figure III.3 contains the doses from the 14N(n,p)14C 
contribution whereas Figure III.4 depicts doses without the proton dose.  The three curves 
represent the dose to the nuclei, cytoplasm, and interstitium.  As the separation between 
the cells increases, the dose to the nuclei and cytoplasm decreases since there is less dose 
from neighboring cells due to the short range.  Likewise, the volume of the interstitium 
receiving a dose from a cellular source remains nearly constant (when cells are close 
together, some of the ion tracks will go from one cell to another but  
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Figure III.3  Dose versus cell edge to edge separation for spherical cells of radius rc = 
4.0 µm, nuclei of radius rn = 3.0 µm, and eccentricity of ε = 0 for boron concentraions of 
10 ppm in the interstitium, 50 ppm in the cytoplasm, and 50 ppm in the nuclei.  Dose 
includes contributions from the boron (n,α) and nitrogen (n,p) reactions. 
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Figure III.4  Dose versus cell edge to edge separation for spherical cells of radius rc = 
4.0 µm, nuclei of radius rn = 3.0 µm, and eccentricity of ε = 0 for boron concentrations of 
10 ppm in the interstitium, 50 ppm in the cytoplasm, and 50 ppm in the nuclei.  The dose 
includes contributions only from the boron (n,α) reaction. 
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the effect falls off rapidly as seen by the nuclear dose).  As the cellular separation 
increases, the percentage of the interstitial volume receiving a dose originating inside of a 
cell decreases.  These effects and the implications for the efficacy of treatment will be 
discussed further in subsequent sections.  
 Since the destruction of the nucleus is generally considered the goal of radiation 
therapy, Figure III.5 contains the nuclear dose as a function of cell edge to edge 
separation for both cases, i.e. with and without the dose from the 14N(n,p)14C reaction.  
The nuclear dose curves are seen to be the same shape with a mean difference of 1.68 Gy 
with good correlation between the two curves.  The proton dose is seen to be ~12% 
higher in the asymptotic tail ( ≥ 10 µm separation) than the dose from the 10B(n,α)7Li 
reaction alone.  Since, in the current models, the nitrogen distribution is homogeneous, 
the 14N(n,p)14C reaction will produce a constant additive dose of ~2 Gy.  Other authors in 
the field of BNCT microdosimetry either omit the dose from the 14N(n,p)14C reaction or 
model it as a homogeneous distribution.  In order to understand spatial variability, the 
dose from the 14N(n,p)14C reaction will generally be omitted unless otherwise stated. 
 
3. Gamma ray dose from the 10B(n,α γ)7Li reaction 
 In 93.7% of the 10B interactions, a γ-ray is produced as is shown in equation 
(III.A.9).  This 480 keV γ-ray is penetrating which means that only a portion of the γ-ray 
energy will be deposited into the tissue with much of the energy being deposited outside 
of the body.  Nonetheless, it is an important dose component to be considered.  For the 
10B(n,α)7Li and 10B(n,α γ)7Li reactions in equations (III.A.9) and (III.A.10), the thermal 
neutron cross section is: 
(III.A.12)  bσ = 3837 . 
The accepted 10B concentration in the cytoplasm and the nuclei is ~50 ppm while the 
interstitial concentration is ~10 ppm.114, 115, 126  The interstitium occupies ~15% of the 
volume for the brain with cells and cytoplasm occupying the remaining volume56, 267 so 
the number density may be determined starting with the relative tissue composition: 




Figure III.5  Nuclear dose versus cell edge to edge separation for spherical cells of 
radius rc = 4.0 µm with nuclei of rn = 3.0 µm and eccentricity of ε = 0 for boron 
concentraions of 10 ppm in the interstitium, 50 ppm in the cytoplasm, and 50 ppm in the 
nuclei.  The dose includes contributions from the boron (n,α) and nitrogen (n,p) reactions 
for the upper curve and only from the boron (n,α) reaction for the lower curve. 
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. 
The γ-ray energy from the 11B metastable nuclear decay is: 
(III.A.15) -14  0.48 MeV/interactions =7.69x10  J/interactionsEγ = . 
The total number of interactions is given by: 
(III.A.16) I Nφσ=  




xφ = 4  
so that that the total number of interactions given by Equation (III.A.16) is 
(III.A.18)







Now consider an infinite medium, so that all of the γ-ray energy will be deposited 
in the medium.  Then the total dose will be given by 
(III.A.19) JI 2.89 3.15 Gy
kg
D Eγ γ= = = . 
The mass energy-absorption coefficient 0.48 MeV γ-ray in human brain tissue may be 
determined from the Tables of X-Ray Mass Attenuation Coefficients and Mass Energy-
Absorption Coefficients at the National Institute of Standards and Technology (NIST) 














ρ = 0.99 . 
By combining (III.A.20) and (III.A.21) energy-absorption coefficient, µen, is: 
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(III.A.22) -10.032 cmenµ = . 
Considering the mean chord length in a convex volume can approximate a mean distance 
likely to be traversed by the γ-ray.  The Cauchy relation for the mean chord length in a 
convex volume provides such an approximtion:268, 269 
(III.A.23) 4 Vl
A
= ∗  
where V is the volume of the object and A is the area.  So for a sphere of radius r, the 
mean chord length is: 
(III.A.24) 4
3
rl = . 
In the present case of microdosimetry, the region of interest is small cubes of side 
approximately 150 µm corresponding to a volume of 3.375 x 106 µm3 = 3.375 x 10-6 cm3.  
The cube can be approximated by a sphere of the same volume which would then have a 
radius, r = 9.3 x 10-3 cm.  The mean chord length is then 
(III.A.25) 




= = . 
The dose to the sphere may then be given by: 
(III.A.26) 2 41 6.24 10 Gy
enl







= − = 
 
. 
Extrapolation to the whole brain is difficult because less is known about the distribution 
of boron for the entire brain.  A typical glioblastoma may easily be 2-4 cm in diameter 
(some may be quite large but would not be a candidate for any present clinical trials) so 
consider a 4 cm diameter tumor that would have a volume of 33.51 cm3 with a boron 
concentration of 44 ppm [see equation (III.A.13) above].  The remainder of a typical 
1400 cc brain270 would have a concentration of ~10 ppm.  Let us first consider an infinite 
medium of uniform distribution defined by: 
(III.A.27) 33.51 1400-33.51 mgN = 44 ppm + 10 ppm  = 10.81 ppm = 10.81 kg1400 1400
   
   
   
. 
So for an infinite medium: 
(III.A.28) 12 interactionsI N 9.24 10 kgxφσ= =  
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using the construction of equation (III.A.19) the total γ ray dose is: 
(III.A.29) J0.768 0.768 GykgDγ = = . 
The volume of a typical human brain is on the order of 1400 cc270so approximating the 
brain by a sphere of volume V = 1400 cc, then the radius is r = 6.94 cm.  So that the mean 
chord length is: 
(III.A.30) 9.253 cml =  
giving a tumor dose of 









= − = 
 
. 
Equations (III.A.26) and (III.A.31) show that, on the microdosimetric or 
macrodosimetric scale, the γ-ray from the 10B(n,α γ)7Li reaction adds a small dose as 
compared to the doses on the order of 10-15 Gy for the microdosmetric region and will 
be ignored in the present work. 
 
4. Dose due to recoil protons 
As was discussed in III.B.1, most of the neutrons are thermalized at the depth of 
the tumor that is usually a few centimeters into the brain.  Protons are bound as hydrogen 
atoms in organic molecules, most commonly to carbon and oxygen.  The bond energies 
may be found in many standard chemistry texts and have values of: 
(III.A.32) J413 4.28 eV
moleH CE − = =  
and 
(III.A.33) J498 5.16 eV
moleH OE − = = . 
Low energy n-p reactions will largely demonstrate elastic scattering which has a rather 
flat cross section of ~20 b versus incident neutron energy over the entire range under 
consideration as shown in Figure III.6. 
As previously shown for elastic scattering reactions in a low energy range in 
equation (III.A.2), for energy ranges from 0 p nE E≤ ≤ , the average energy of the free 
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Elastic Proton Scattering Cross Sections
Incident Neutron Energy (MeV)






















Figure III.6  Elastic scattering cross sections for protons as a function of incident 
neutron energy displaying a relatively flat distribution in for the incident neutron energies 
used in BNCT obtained from ENDF data set at the National Nuclear Data Center. 
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recoil proton is half that of the incident neutron.  The binding energy of the hydrogen to 
its parent organic molecule decreases the recoil proton kinetic energy in the following 
manner: 
(III.A.34) ' 1
2p p B n B
E E E E E= − = −  
where pE′  is the net recoil proton energy and EB is the binding energy which for this 
discussion is either equation (III.A.32) or (III.A.33).  Equation (III.A.34) defines a 
minimum average energy that the neutron must possess in order to break the bond and 
leave the proton with energy 0pE′ =  so that the neutron must possess: 
(III.A.35) 2
n BE E≥  
in order to break free from the molecule.  Thus, the neutrons must have more than ~10 
eV of energy to generate recoil protons.  Thermal neutrons with energies on the order of 
0.025 eV will not have sufficient kinetic energy to break the common hydrogen bonds. 
 Neutrons that have not yet been thermalized can potentially break the chemical 
bonds as long as equation (III.A.35) is satisfied.  So, for the H-C bond, the neutron will 
have more than 8.56 eV of kinetic energy while the energy required to break a H-O bond 
with elastic scattering would have to be greater than 10.32 eV.  If the neutron kinetic 
energy is equal to the bond energy, the bond will be broken but the particle will have no 
kinetic energy to dissipate and so provides no dose.  Also, it is important to remember 
that especially low energy neutrons, i.e. those with a few eV of kinetic energy, may 
excite vibrational modes in the molecule to which the hydrogen is bound so that not 
every interaction of sufficient energy will produce a recoil proton.  The exceedingly large 
number of different molecular species found in humans with complex vibrational 
excitation patterns makes the estimation of this mode of energy dissipation beyond the 
scope of this work.  The dose, D, may be determined similarly as was shown in equations 
(III.A.16), (III.A.17), and (III.A.19) above.  For the H-C bonds, the results are 
summarized in Table III.4 where the fluence has been taken as 4 x 1012 n/cm2.  The 
neutron energy distribution as a function of depth can only be measured in phantoms or 
in animals so that the actual fluence is not well known so that these doses can be viewed 
as the upper limits of the potential dose.  Thus, the recoil protons constitute a small  
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Table III.4  Elastic proton scattering as a function of incident neutron energy. 
Neutron 
Energy (eV) 




10 0.72 20.16 5.56 x 10-4 
100 45.72 20.15 0.035 
1,000 495.72 20.05 0.38 
10,000 4995.72 19.20 3.67 
 
 
additive dose to the total dose with the dose distribution being homogeneous due to the 
ubiquitous presence of hydrogen in organic molecules. 
 Finally, it is important to determine the range of the recoil protons so that the 
implications for microdosimetry may be better understood.  Using the program SRIM 
that is commonly used for targetry, ion deposition, and in the BNCT community to 
calculate the range, the proton ranges are listed in Table III.5.  The dose from recoil 
protons is deposited in the immediate region of the hydrogen, i.e. in the cell in which the 
interaction occurs.  Thus, the dose from recoil protons is a small contribution to the 
microdosimetry in BNCT that has no understood spatial variability.  For the present 
study, the dose due to the recoil protons will not be included. 
 
5. Dose from the 1H(n,γ)2H reaction 
The cross section for thermal neutron capture by hydrogen is not small and 
hydrogen is found in abundance in all organic molecules.  The treatment of the γ-ray 
produced will be handled in a similar manner, as was the γ-ray from the BNCT reaction.  
In addition to elastic and inelastic scattering events, some of the thermal neutrons will be 
captured by the hydrogen nucleus which will emit a 2.22 MeV γ-ray in the following 
reaction: 
(III.A.36) 1 21 1 (2.22 MeV)n H H γ+ → + . 
The cross section for thermal neutron capture by a hydrogen nucleus may be found online 
at the National Nuclear Data Center and is: 
(III.A.37) 2 bσ = 0.33 . 
where the γ-ray energy from the capture of the neutron by the proton is: 
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Table III.5  Recoil proton range for various epithermal neutron energies with totally 













10000 5000 1314 0.1314 
1000 500 166 0.0166 
100 50 22 0.0022 
10 5 4 0.0004 
 
 
(III.A.38) 13  2.2 MeV/interactions 3.56  10  J/interactionsE xγ −= = . 
The concentration of 1H in human tissue is ~10% by weight so using the same 
calculations as in prior subsections the number density is: 
(III.A.39) 125 H atomsN 5.97 10 kg tissuex= . 
The total number of interactions is given by Equation (III.A.16) and for this case 
becomes: 
(III.A.40) 13 interactionsI 7.93 10 kgx= . 
As was done previously, consider an infinite medium so that all of the γ-ray energy will 
be deposited in the medium so by using the form of (III.A.19) the γ−ray dose is: 
(III.A.41) J28.22 28.22 GykgDγ = =  
The mass energy-absorption coefficient for a 2.0 MeV γ-ray in human brain tissue may 
be determined from the Tables of X-Ray Mass Attenuation Coefficients and Mass 
Energy-Absorption Coefficients at the (NIST) online site: 





where the density for human brain tissue is given in Equation (III.A.21) so that  
(III.A.43) -10.026 cmenµ = . 
As before, for a typical human brain volume of 1400 cc the brain can be approximated by 
a sphere of volume of radius r = 6.94 cm. so that the mean chord length is: 
(III.A.44) 9.25 cml = . 
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The dose to the whole brain is then 
(III.A.45) 21 0.11 3.16 Gy
enl







= − = = 
 
 
In the case of microdosimetry, the region of interest is much smaller.  In the present case 
the larger regions of interest are approximately cubes of side ~150 µm corresponding to a 
volume of 3.375 x 106 µm3 which could be approximated by a sphere of the same volume 
with a radius of r = 9.3 x 10-3 cm.  Then the mean chord length becomes 
(III.A.46) 0.0124 cml =  
which results in a dose to the region of interest of 
(III.A.47) 34.94 10 GyD x −= . 
On the macrodosimetric scale, with doses to the normal brain dose of 2-3 Gy and tumor 
dose of 30-61 Gy,95 or on the microscopic scale of 10-15 Gy, presented herein, the dose 
from the 1H(n,γ)2H reaction adds a small component to the total dose.  The dose from the 
radiative capture reaction will thus not be included in the present study. 
 
6. Summary of the components to the radiation milieu 
 Several authors have reported that the 10B(n,α)7Li reactions account for 
approximately 86% of the total dose.7, 271  The present work can then be compared to 
these earlier works providing further evaluation of the code.  In order to compare the 
results, a case was run with cells of radius 5.0 µm, nuclear radius 4.0 µm, eccentricity of 
ε = 0, and a separation of 0.0 µm.  The dose from recoil protons is dependent upon the 
details of the neutron beam.  Figure III.2 showed that a typical neutron beam has a rather 
flat neutron energy distribution in the requisite energy range.  Furthermore, the elastic 
cross sections as a function of incident neutron energy is also flat in the epithermal 
energy range as was shown in Figure III.6.  So the elastic proton doses can be averaged 
as an approximation of the actual dose.  The results are presented in Table III.6.  The 
agreement is quite good especially since there are no contributions from neutron beam 
contaminants as discussed above. 
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Table III.6  Dose contribution from different radiation components. 
Radiation Component Dose (Gy) Percent of 
Total (%) 
10B(n,α)7Li 43.12 89.8 
14N(n,p)14C  3.79  7.9 
γ from 10B(n,α)7Li    0.099   0.21 
1H(n,γ)2Η     0.0049   0.01 
Elastic recoil protons 1.02   2.12 
Totals 48.04 100.0 
 
 
C. How the boron distribution affects the dose 
 
 As the boron concentration increases in a region, the number of boron interactions 
will increase proportionately.  Since the dose is localized, the result should be scaled in a 
linear manner.  Figure III.7 shows a typical case for spherical cells of radius rc = 5.0 µm 
with spherical concentric nuclei of radius rn = 4.0 µm where the dose in seen to be higher 
when the cells are closer which will be dealt with in more detail later.  In the asymptotic 
region where the cells are too far apart to affect each other, the nuclei and cytoplasm 
receive a larger dose than dose the interstitium where the concentration is a fifth that of 
the cells.  In order to better understand the role of the boron concentration, the dose may 
be broken into components.  The components may be calculated by setting the boron 
concentration to zero in two of the three regions with the remaining region having the 
concentration as depicted in Figure III.7.  Examining the nuclear dose only in Figure III.8 
it is seen that the sum of the three component curves produces the independently 
calculated upper curve from Figure III.7 demonstrating the linearity of the dose in a given 
region as a function of the boron concentration.  Of note is the small increase noted in the 
first portion of the nuclear dose when all of the boron is in the interstitium.  The increase 





Figure III.7  The dose for the three regions of interest for typical cell sizes of radius rc = 
5.0 µm with spherical concentric nuclei of radius rn = 4.0 µm and boron concentrations 
that have been experimentally determined as 50 ppm in the cells and 10 ppm in the 
interstitium. 
Dose as a function of separation
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Figure III.8  The nuclear dose only for typical cell sizes of radius rc = 5.0 µm with 
spherical concentric nuclei of radius rn = 4.0 µm and boron concentrations that have been 
experimentally determined.  The three lower curves are the produced by allowing only 
one of the three regions of interest to have boron with the remaining two regions to have 
a boron concentration of zero.  The sum of the lower three curves is seen to produce the 
independently calculated upper curve. 
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containing interstitial space as the cells separate.  A similar effect is seen in Figure III.9 
where only the dose to the interstitium is shown.  The three lower curves are once again  
seen to sum to the independently calculated upper curve.  The interstitial dose when all 
the boron is concentrated in the interstitial space is of interest since it is seen to increase 
with separation.  This is because when the cells are close together a larger proportion of 
the ions will deposit energy into a cell than into the interstitium.  As the cells separate, a 
larger proportion of the ions will have their entire track in the interstitium. 
 Also of interest are cases where the ratio of cellular boron to interstitial fluid and 
normal cells is higher than has been currently seen with BPA as the boron carrier 
molecule.  Early animal experiments have produced ratios of 10-20:1 which would mean 
100-200 ppm in the cells with 10 ppm in the interstitial fluid and normal cells.121  The 
effect of these ratios is seen in Figure III.10 where the corresponding nuclear and 
interstitial curves are seen to be twice the dose at 200 ppm in the cells compared to 100 
ppm.  The cellular doses are seen to be enormous and the scaling is again seen to be 
linear.  These potentially obtainable doses are truly remarkable when it is remembered 
that the lethal free air whole body dose required for a 95% lethality is ~7 Gy.  The most 
important aspect of Figure III.10 is that the nuclear dose is >50 Gy even for widely 
separated cells for the 200:1 cell to interstitium boron concentrations.  So that active (in 
the sense of avidly accumulating the boron carrier molecule) tumor cells will be 
destroyed with doses as high as 65 Gy for nuclei in the body of the tumor.  At the same 
time, the surrounding tissue will receive < 5 Gy which is a reasonable dose.  The normal 
tissue will be preserved with much more effective killing of tumor cells even if widely 
separated.  Thus, as new boron carrier molecules are produced that increase the tumor to 
normal tissue ratio, the effectiveness of the modality will likewise increase. 
 
D. The effects of cell geometry on the dose 
 
 The hypothesis of this dissertation is that cells closely packed together will 
provide a significant dose to neighboring cells as well as to the interstitial space which in 
the present model contains normal cells and cells in the G0 (resting) phase.  The model 
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Interstitial dose for different boron concentrations
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N:   0,   C: 50,   I:   0
N:   0,   C:   0,   I: 10
 
 
Figure III.9  The interstitial dose only for typical cell sizes of radius rc = 5.0 µm with 
spherical concentric nuclei of radius rn = 4.0 µm and boron concentrations that have been 
experimentally determined.  The three lower curves were produced by allowing only one 
of the three regions of interest to have boron with the remaining two regions to have a 
boron concentration of zero.  The sum of the lower three curves is seen to produce the 
independently calculated upper curve. 
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Nuclear and interstitial doses for different boron concentrations
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Interstitial dose for 200 ppm boron
Nuclear dose for 200 ppm boron
 
 
Figure III.10  The dose for the three regions of interest for typical cell sizes of radius rc 
= 5.0 µm with spherical concentric nuclei of radius rn = 4.0 µm and boron concentrations 
that are potentially achievable with new boron carrier molecules of 200 ppm in the cells 
and 100 ppm in the cells with 10 ppm in the interstitium in both cases. 
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permits dose variance estimations to both the cells and the interstitium as the cells are 
separated.  Observing the separation of the tumor cells corresponds to examining the edge 
of tumors.  The cells will gradually thin out until they are more widely separated.  This 
situation is especially true for infiltrative tumors such as GBM but less so for other 
tumors such as melanoma which tends to be more circumscribed with few cells separated 
from the main tumor body.  In order to understand the actual in vivo microdosimetry, 
boron concentrations will be set as 10 ppm in the interstitium, 50 ppm in the cytoplasm, 
and 50 ppm in the nuclei, which is similar to the determinations of boron concentrations 
in actual patients as determined by Coderre, et. al.,115, 272 unless otherwise specified.  The 
size and shape of normal cells is quite variable with cells varying from small (on the 
order of 3-4 µm in radius) to those up to radii of over 10 µm.  Likewise, nuclei can vary 
from a radius of 1-2 µm up to 8-10 µm for some types of tumor cells.  Cell shapes are 
also quite variable.  Some are small, almost cuboidal, as in the Kupffer cells in the liver, 
others are spherical (especially in white blood cells such as lymphocytes and monocytes), 
and some are elongated such as myocytes (muscle cells) and neurons.273-275  Spinal 
neurons may be more than a meter in length extending from the cell body in the upper 
lumbar spine to the foot.  Tumor cells typically display more variability in size and shape 
than the tissues from which they arise especially in regards to the nuclei which are often 
larger and more eccentric in shapes.10, 276, 277  Furthermore, new studies are demonstrating 
that living cells are constantly changing shape responding to the local biochemical and 
physical milieu.  The programs written for this dissertation are designed for ellipsoidal 
tumor cells.  But by simply changing the underlying geometry, the microdosimetry of 
different tumors may be modeled.  For example, closely packed spherical cells simulate 
melanoma whereas a very eccentric geometry with spherical nuclei far from the cell 
center better approximates neurons. Glioblastoma multiforme cells are somewhere in 
between these two geometries.  So to understand the microdosimetry of BNCT, several 
cases will be considered. 
 Figure III.7 shows the effect of separating cells that initially are just touching and 
gradually move apart.  The figure shows a 16% increase from the asymptotic ‘tail’ to the 
peak when the cells are just touching. This means that the nucleus of each cell receives an 
 79
additional dose from neighboring cells which could be viewed as a near neighbor effect.  
Also, significant is the ratio of 2.46 of the maximum of the interstitial dose when the cells 
are just touching to the dose in the asymptotic tail of the interstitial dose.  The then 
interstitium receives a significantly larger dose from neighboring cells.  As the cell radius 
increases, the effect on the nuclei diminishes if the nuclear radius does not increase in a 
like manner.  This decrease in effect can be seen in Figure III.11 for spherical cells of 
radius 8.0 µm and a nuclear radius of 4.0 µm.  The dose to the nuclei is essentially flat 
whereas the dose to the interstitium shows the earlier noted effect.  The explanation has 
to  with the short range of the ions.  The maximum range of the alpha particle from the 
10B(n,α)7Li and 10B(n,α γ)7Li reactions (refer back to Table II.2) is 9.06 µm (6.3% of the 
time) and 7.39 µm (93.7% of the time) for a mean range of ~7.5 µm.  Similarly, the mean 
range of the lithium nucleus is ~4 µm.  When the cell radius is 8.0 µm and the nuclear 
radius is 4.0 µm, a boron disintegration must be near to the cell edge along a line of 
centers for the ions to reach the nearest neighbor nucleus.  When the cell edges are 1 µm 
apart, essentially no lithium ions reach the nearest neighbor nucleus and when the edges 
are 5 µm apart there is no contribution from the alpha particles.  Also, the particles are 
losing energy along the track as defined by the stopping powers defined in chapter III so 
that the tail of the particle tracks deposits little energy into the neighboring nucleus.  
Figure III.11 contains a summary of the dose as a function of separation for cells when 
the cell radius is 8.0 µm and the nuclear radius is 4.0 µm.  The decrease in the nuclear 
dose is clearly demonstrated in Figure III.11 where there is a small decrease in the dose 
over the first 2-3 µm.  Thus, the geometry of the cells has an impact upon the nuclear 
doses.  The interstitial dose is affected in a similar manner, with the magnitude of the 
effect (peak dose/asymptotic dose) is lower than that presented in Figure III.7.  The ratio 
of peak dose/asymptotic dose for the smaller cells (Figure III.7) is ~2.3 versus the larger 
cells where it is ~1.9 (Figure III.11).  This effect can be understood by first examining the 
packing fraction of a region defined for this case as the total volume inside the cells 
(ellipsoids) divided by the total volume of the region of interest.  So consider a cube that 
encloses eight spheres of radius r so that the cube has side l = 2*(2r) = 4r and the volume 
of the cube is: 
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Effects of separation on large spherical cells
Cell edge to edge separation (µm)

















Figure III.11  Dose as a function of cell edge to edge separation for large spherical cells 
of radius rc = 8 µm with nuclei of rn = 4 µm for boron concentration of 10 ppm in the 
interstitium, 50 ppm in the cytoplasm, and 50 ppm in the nuclei demonstrating the 
increase in dose to neighboring cells and interstitium (at small separations).  The effect is 
less than that observed with smaller cells. 
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Figure III.12 contains a summary of the average dose to the interstitium over 50 cases at 
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The fit is seen to be rather good, meaning that part of the explanation for the smaller dose 
has to do with the fact that the surface area is increasing less rapidly than the boron 
containing cell volume.  However, the fit does not satisfy Equation (III.A.51), which 
suggests that there are other factors that must be considered such as ions that pass from 
one cell to another.  The basic observations are that near neighbors contribute to the dose  
of a cell and that, when cells are widely separated, the dose to the interstitium decreases.  
These findings have significant implications for the types of tumors that can be treated 
with BNCT as will be discussed in the chapter IV. 
 The effects of the cell radius and cell separation are shown in Figure III.13 for the 
interstitial dose.  The dose in the interstitium is highest when the cells are small and  
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Intersitital dose versus cell radius at a separation of zero
Cell radius (µm)





















Figure III.12  Interstitial dose averaged over 50 cases with no separation at four cell 
radii.  Fitting is performed non-linearly with the function D = D0 + a0/r as derived from 
the ratio of the surface/volume for spheres.  Nonlinear regression was used to fit the data 














































Figure III.13  The dose to the interstitium as a function of cell radius for a concentric 
nucleus of radius 3.0 µm and cell edge to edge separation for boron concentrations of 50 
ppm in the cell (nucleus and cytoplasm) and 10 ppm in the interstitium. 
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densely packed.  As the cells increase in radius or the cells are farther apart, the dose 
decreases and, if both occur, the dose can decrease by a factor of 2.  Thus, normal tissue 
will receive lower doses when the tumor cells are far apart and large.  The corresponding 
nuclear dose for the same geometries is shown in Figure III.14.  The data in this figure 
reveal that the nuclear dose decreases as the cells become more separated but increases as 
the cells increase in size.  For large cells, there is little change as the cells separate for the 
concentric nuclei.  Thus, large tumor cells display less near neighbor effects because of 
the distance to the nucleus.  Since the idea of BNCT is to deliver a significantly larger 
dose to the tumor than is delivered to normal tissue, it is useful to plot the ratio of the 
total cellular dose to the interstitial dose, which, represents normal tissue, as a function of 
separation and cell radius.  The results are plotted in Figure III.15 where it is clear that 
normal cells far from the tumor will have a greater therapeutic benefit than those near or 
in the tumor.  This once again demonstrates the effects of neighboring cells on the dose.  
In Figure III.16, the relative dose to the nucleus, as compared to the cytoplasm is plotted 
as a function of the cell radius for cellular boron concentrations of 50 ppm and 200 ppm 
while the interstitial boron concentration is 10 ppm for each case.  The slight proportional 
decrease in dose to the nuclei is geometric for the increasing cytoplasmic volume in 
which an ion can travel without encountering the nucleus.  As the nuclear volume goes 
from 51.2% of the cell volume for a nuclear radius of 4.0 µm and a cell radius of 5.0 µm 
to 4.8% when the cell radius increases to 11 µm, any given ion is more likely to deposit 
all of its’ energy in the cytoplasm rather than in the nucleus. 
 The implications of these results combined with an improved boron carrier are 
obvious.  Consider cells of radius 10 µm with concentric nuclei of radius 4 µm separated 
from one another by 20 µm and boron concentrations of 200 ppm in the cell and 10 ppm 
in the interstitium.  In this situation, the boron reaction dose would be 5.82 Gy to the 
interstitium, 62.71 Gy to the cytoplasm, and 82.28 Gy to the nuclei.  The interstitial dose 
is still reasonable while the nuclear dose is quite high with a nuclear to interstitial dose 
ratio >15.  This would kill all cells that concentrated the boron carrier molecule with little 
damage to normal tissue in a single treatment.  The patient could receive subsequent 



































Nuclear dose for spherical cells with 











Figure III.14  The nuclear dose as a function of cell radius for a concentric nucleus of 
radius 3.0 µm and cell edge to edge separation for boron concentrations of 50 ppm in the 


























































Figure III.15  The ratio of the dose to the cell to the dose to the interstitium as a function 
of cell radius and cell separation for boron concentrations of 50 ppm in the cell (nucleus 
and cytoplasm) and 10 ppm in the interstitium. 
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Nuclear to cytoplasmic dose ratio
as a function of cell radius
Cell radius (µm)
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Figure III.16  The relationship of the nuclear to cytoplasmic dose ratio for two different 
cellular boron concentrations and for varying cell radii.  The noisiness in the 50 ppm 
boron concentration data is due to the smaller number of boron reactions in total as well 
as the smaller proportion of the total number of reactions for the region of interest, i.e. 
20:1 versus 5:1. 
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 or resting state.  The combination of boron distribution and tumor cell architecture has an 
enormous impact upon the dose to the tumor cells. 
 The eccentricity of an ellipsoid is a measure of how far the ellipsoid is from 
spherical.  One method of defining the three axes of an ellipsoid (commonly used in 
nuclear physics because the volume remains constant as the eccentricity or deformation 
changes) was previously described in equations (II.A.22) and (II.A.23).246  As shown in 
equation (II.A.24), the volume, defined by a sphere of radius r, remains constant as the 
eccentricity varies.  This definition of an ellipsoid also possesses rotational symmetry 
about the a axis.  When ε equals zero, the ellipsoid is a sphere.  As ε gets larger, the 
ellipsoid becomes more elongated, which is referred to as prolate as shown in Figure 
III.17.  Eccentricities in the range –1 < ε < 0 lead to a flattened (pancake) shape referred 
to as oblate.  Another view of the ellipsoidal cells is seen in the two cross sections of an 
ellipsoidal cell shown in Figure III.18 with a radius of 10 µm and eccentricity of 2.5 
encompassing a nucleus of radius 4 µm.  To determine the effect of the eccentricity on 
dose, the ratio of the nuclear dose for an ellipsoid with a radius of 10 µm to the dose of an 
equivolume sphere both with concentric nuclei is shown as a function of eccentricity and 
cell separation in Figure III.19.  The plot is essentially flat indicating that the response is 
like that just described for large spherical cells.  Ellipsoidal cells can be approximated by 
spherical cells especially for understanding effects rather than numerical values. 
 Finally, the nucleus can be allowed to be eccentrically centered.  It can be 
randomly eccentrically centered in every cell, randomly eccentric in the first cell that is 
then applied to all subsequent cells, or a fixed direction or a fixed distance from the 
center specified with the other parameter randomly determined.  The results from this are 
of interest because there is essentially no difference between the spherically concentric or 
randomly placed nuclei.  The results are surprisingly similar.  For example, the su m of 
the squares difference between spherical cells of radius 10 µm with concentric spherical 
nuclei of radius 4 µm and spherical cells of radius 10 µm with randomly placed spherical 
nuclei of radius 4 µm is 0.06.  The data are very similar to those for concentric spherical 










Figure III.18  Two cross sections through a cell with eccentricity of 2.5 and radius of  











































Comparison of the dose to an ellipsoidal cell





Figure III.19  A comparison of the dose to an ellipsoidal cell and an equivolume sphere 
both with concentric nuclei of radius 4.0 µm.  The spherical cell and ellipsoidal cell have 
the same radius of 10 µm.  For an eccentricity of ε, the three axes (a, b, and c) of the 




IV. Summary and Conclusions 
 
 The information presented in chapter III leads to the conclusion that boron 
distribution, cell geometry, and the cell’s relationship to other cells are important factors 
in determining the total dose delivered to a given nucleus.  The dose to the nucleus is 
considered by experts in the field as the important radiation dose, destroying the cell’s 
ability to make essential proteins to maintain homeostasis.  Damage to the DNA can also 
lead to the inability to undergo successful mitosis leading to death or a halt to further 
replication (either case is a success in cancer control).  Lastly, damage to the DNA can 
lead to advanced apoptosis, i.e. the programmed cell death is temporally advanced.  So 
the results in chapter III are viewed from the standpoint of the nuclear dose. 
 The interpretation of the results must take into account the region termed as 
interstitium in this work.  Technically, the interstitium is the fluid filled space between 
cells in a tissue.  In this work, the interstitium refers to the space between tumor cells or 
more specifically between cells loaded with boron.  So in this model, the interstitium can 
also contain normal cells or tumor cells that do not avidly uptake the boron carrier by 
either active or passive means.  The dose to the interstitium in tumors such as malignant 
melanoma and adenocarcinoma of the colon represents the dose to the normal tissue so 
that low doses are important.  In infiltrative tumors such as glioblastoma multiforme and 
angiosarcoma, the interstitium will contain both normal cells and tumor cells that did not 
avidly uptake the boron agent.  This has significant clinical significance as will be 
discussed. 
 Considering the above observations, there are several ways to summarize the 
results from chapter III.  First, returning to Figure III.7, it was shown that there is a 16% 
increase in the nuclear dose when the cells are touching each other versus being widely 
separated.  Whereas the dose to the interstitium is ~2.4 greater when the cells are 
touching than when widely separated.  Thus, closely packing cells increases the nuclear 
dose, which will improve the efficacy.  The much greater increase in dose to the 
interstitium means that cells without boron loading will receive a significantly larger dose 
when cells are close together but a small dose when they are apart.  Furthermore, the ratio 
of the nuclear dose to interstitial dose ratio is greater when the cells are widely separated, 
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with the tumor cells still receiving a dose greater than 15.5 Gy.  Cell death is a statistical 
phenomena and is expressed by a cell survival curve as shown in Figure IV.1.  This 
figure demonstrates that the doses delivered by BNCT are adequate for cell killing.  This 
is especially true when the dose to the cytoplasm is combined with the nuclear dose to 
determine the cellular dose used in the Figure IV.1.  For example, referring again to 
Figure III.7, the cellular dose for no separation is ~32 Gy and for the asymptotic range is 
~27 Gy.  Both doses should clearly be lethal.  
 The distribution of boron in the cell is also seen to be important with the greatest 
dose occurring when the boron is concentrated in the nuclei rather than the interstitium by 
a factor of ~2 as seen in Figure III.8.  The boron in the interstitium provides a small 
nuclear dose and is the most important constituent of the dose to the interstitium itself.  
The greater the concentration of boron in the cell holding the interstitial boron 
concentration constant, the greater the nuclear dose, in a basically linear nature.  The 
effect on the interstitial dose is minimal.  This highlights the dependence of BNCT upon 
boron carrier molecules.  If a carrier molecule can increase the absolute tumor cell boron 
concentration and increase the ratio of cell to interstitium boron, the efficacy of BNCT 
will greatly increase. 
 As cells increase in radius while keeping a constant nuclear radius, the nuclear 
dose will increase and the influence of nearby cells decreases.  Also, the greatest ratio of 
cell to interstitial dose occurs for large separated cells.  The influence of a non-concentric 
nucleus is relatively small for the geometries studied. 
 In summary, the nuclear dose for small cells is increased by nearby cells but 
shows little near neighbor effect for large or greatly separated cells.  The greater the 
boron concentration, the greater the nuclear dose.  If the cell to interstitial boron 
concentration increases as the cellular boron increases, the interstitial dose changes little 
but, if the cellular concentration of boron is linearly increased, this should translate into 
much greater efficacy. 
BNCT has been used to treat several malignancies including glioblastoma 
multiforme, malignant melanoma, head and neck tumors, undifferentiated thyroid 







Figure IV.1  A typical cell survival curve for high and low LET radiation showing 
significant killing for doses predicted for BNCT.295 
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studied tumor is GBM.  As discussed in chapter I, the standard therapy for glioblastoma 
multiforme is neuro-surgical resection followed by 36 standard photon beam radiation 
treatments and in some cases chemotherapy.  This standard protocol provides a life 
expectancy of approximately 12 months from the time of diagnosis.8  The BNCT trials 
substitute BNCT for conventional photon therapy and demonstrate a survivability of 
approximately 14 months.41, 55, 66, 296, 297  The clinical trials have all observed that the 
glioblastoma recurs at the edge of the tumor bed.  Since the tumor is infiltrative, the edge 
of the tumor will be ragged with cells extending into the surrounding tissue.  The 
microdosimetry of BNCT provides an answer.  Consider cells in this periphery that did 
not accumulate a significant boron concentration (in G0 phase or poor local availability of 
the boron carrier).  This would correspond to a cell in the interstitium that is in the widely 
separated region.  These cells will receive only a few Gray of dose (~5 Gy) unlike a cell 
in the interstitium in the tightly packed case with the dose being more than twice that of 
the periphery.  These doses can go from possible to likely lethality.  This model would 
indicate that infiltrative tumors cannot be successfully treated with BNCT with current 
boron carrier molecules.  The reason for the failure of local control has not been clearly 
elucidated before.  The only way that an infiltrative tumor can be successfully treated 
with BNCT is to find an agent that concentrates in tumor cells avidly, even if the cell is in 
the G0 phase, or to administer therapy given over several days.  Though giving dose 
fractions might be successful, fractionating the treatment decreases the attractiveness of 
the therapy when compared to a single session treatment (allowing for multiple beam 
angles in some cases). 
Turning to melanoma and adenocarcinoma of the colon, the results are much 
more favorable.  Brain metastases in malignant melanoma and liver metastases in 
adenocarcinoma of the colon have been successfully treated using BNCT, though the 
patients died of massive tumor load elsewhere.  Microdosimetry provides insight into the 
effectiveness of the treatment for these tumors.  First, initial inferences have 
demonstrated modestly improved boron concentrations in the tumors.79, 100, 150, 271, 294, 298-
303
  The more important issue is the geometry of tumors.  They are more solid (closely 
packed), grow by direct extension, and do not typically have individual tumor cells.  
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Examining the cells on the periphery, once again they are more analogous to a solid 
sphere with the cells on the edge in close contact with the main tumor body.  The 
microdosimetry model predicts that all of the cells would be close together so that even 
tumor cells not loaded with boron on the edge of the tumor will receive a reasonable dose 
(~10 Gy).  This would correspond with the clinical results that have demonstrated good 
tumor control.67, 97, 294, 301 
The microdosimetry of BNCT is dependent upon cellular geometry and boron 
concentration.  Clinical results correlate with microdosimetric predictions.  As this 
exciting cancer treatment modality progresses, 18F-BPA will become the standard for 
treatment planning since it can identify the distribution of boron laden cells which, if 
used in concert with the microdosimetric results, will provide a methodology to 
determine the likely efficacy of treatment. 
In conclusion, this dissertation has advanced the understanding of the 
microdosimetry of BNCT in several ways.  The program uses the actual stopping power 
curves to determine the energy deposition for a given ion instead of a linear 
approximation that improves the accuracy.  The effect of neighboring cells on tumor cell 
dose is explored showing a benefit from densely packed cells for the dose to tumor cells.  
The dose to tumor cells that accumulate boron in the same concentration as normal cells 
(the interstitium in this model) receive a significantly larger dose when the boron laden 
tumor cells are closely packed around the non-boron laden cells.  The effects of the 
location of the nucleus within the cell on the dose is described and found to be a small 
effect.  This work agrees with other calculations showing that the nuclear boron 
concentration is the most important component of the nuclear dose.238, 241, 244  Cell size 
and boron concentration correlate with a larger nuclear dose as well as a larger dose to 
surrounding normal cells if the separation of the boron laden tumor cells is small.  The 
data also demonstrate that for widely separated tumor cells, i.e. ITCs, there will be a 
relatively small dose of only ~4-5 Gy for tumor cells accumulating boron in the same 
manner as normal cells and the interstitium.  These results have been compared to actual 
clinical results in order to explain the clinical observations.  The microdosimetric model 
presented is shown to explain the clinical results.  This serves to validate the usefulness 
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of the study of the microdosimetry of BNCT.  Thus, this dissertation advances the field 
and clinical understanding of boron neutron capture therapy. 
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V. Future Directions for Research into Boron Neutron 
Capture Therapy Microdosimetry 
 
 As discussed, a primary problem for microdosimetric modeling is geometry, i.e. 
how to best represent the cells and their sub-structures.  Another problem is the paucity of 
data relating to the stopping powers for the ions in BNCT in the low energy portions of 
their tracks (< 1 MeV/amu).  The continuous slowing down approximation (CSDA) could 
be replaced by a more realistic step function approach since some of the energy loss is 
quantum mechanical and thus not continuous.  A better theoretical treatment seems 
unlikely at this time due to the great complexity of the interactions with the partially 
charged ions due to less than maximal ionization as the heavy ions slow down to much 
less than relativistic speeds.  In the low energy spectrum for the stopping power 
calculations, the quantum mechanical effects of the target electrons (especially electrons 
in the outer shells) play a significant role in two ways.  The first is by the direct 
interaction of the electron cloud with the ions, which changes the velocity of the ions.  
Also, the nearly free outer shell electrons partially shield the ion, effectively changing the 
charge state, z, to z* such that 1 < z*/z.  The diminution of the ion charge obviously also 
alters the electromagnetic interaction between the ion and the electron clouds.  The partial 
shielding represented by z* is obviously an idealization of the quantum mechanical 
interactions that are occurring where an electron binds to the ion for a short time and is 
averaged to a partial charge.  The second effect is the creation of large numbers of delta 
waves (secondary electrons from an ionization process), which alters the local charge 
milieu, creates many free radicals, and adds to the microdosimetric dose.  The production 
of delta waves may in fact be the most significant portion of any dose of ionizing 
radiation.   The number of these interactions increases per unit track length traversed 
because, as the charged particles start to slow down, there is more contact time for the 
interactions to occur which increases the production of delta waves.  It cannot be over 
emphasized that the experimental data in the low energy region (< 1 MeV/amu) often 
varies as much as 20% and that binding energies for organic bonds are on the order of a 
few eV.  Thus, the effects of better stopping power data is of great importance to the 
understanding of microdosimetric processes.  The complexity of the theoretical problem 
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is too great at this time to allow a model capable of accurate predictions.  Therefore, it is 
likely that improvements will have to be made in measurements of the stopping powers in 
actual tissue.  Unfortunately, there is little interest from national funding agencies at this 
time to extend this research.  The data obtained from SRIM2008 are probably reasonable 
at this point in time with the current understanding of all of the other aspects of 
microdosimetry.  SRIM2008 has become the accepted standard in microdosimetry.  As 
the field moves forward, the need for better stopping power data will become a more 
significant problem. 
 A more complete array of the radiation components that contribute to the total 
dose could be added to the Dose program.  This would aid in determining likely peak 
doses.  This would be a straightforward addition to the dose.  Allowing for γ-rays and fast 
neutrons from beam would be reasonable.  Addition of the dose from beam derived γ-rays 
would be straightforward but the contributions from fast neutrons will be more 
challenging.  Fast neutrons have more varied nuclear reactions that will need to be 
included. 
 The other area in which this model could be improved is related to the geometry 
of the cells.  Attempting to construct a more representative cell, without creating complex 
shapes out of simple geometric figures, is a rather daunting project.  It would appear that 
the relatively new field of chaos presents the possibility of constructing more realistic 
cells.  The constructs for the chaos theory may not increase computational time although 
it is always difficult to know where the ion track lies within a cell, etc.  The application of 
chaos theory to microdosimetry seems imminent especially after the positive results 
shown here.  
 Finally, the new field of microbeam technology could be used to study the effects 
of radiation on the cell and its’ organelles.  There is much research being done to better 
understand what damage is done to the nucleus when the radiation deposition is not in the 
nucleus, when it is in the nucleus, and when it is in a neighboring cell.  It is known that 
ionizing radiation causes free radical formation.  The free radicals diffuse away from the 
ionization event causing damage at some distance (on the order of 1 or 2 microns).  These 
free radicals can cause significant DNA damage even though the ionization track lies 
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outside of the nucleus.  These free radicals may induce other chemical species yet to be 
characterized that can damage DNA.  Also, it is known that cells can communicate with 
one another so that the damage or protection inferred upon one cell might be 
communicated to other cells around it.  This exciting area of research will have large 
implications for microdosimetric codes.  The results of such calculations may be 
incorporated rather straightforwardly, into the current code by assuming that a particular 
cell that has a given dose will provide a protective factor and/or, depending on the author, 
a destructive factor to near-neighbor cells.  The effect could be allowed to diffuse through 
the volume of interest.  Adding or subtracting some percentage of the dose around cells 
that receive a given dose is a straightforward way to model this effect.  So that the model 
can be updated rather quickly whenever microbeam research produces pertinent results. 
The microdosimetric model presented here provides a powerful technique to 
evaluate BNCT results.  The model appears to be sufficiently accurate to provide 
predictive information, though ideally more testing should be done before too much 
emphasis is given to any prediction.  Incorporating improved stopping powers or results 
from microbeam technology can also be done in a straightforward manner.  Changes 
involving chaos theory are likely to prove somewhat more difficult.  The level of 
difficulty is based upon how difficult it is to know where any given point lies – in the 
interstitium, the cytoplasm of a particular cell, or the nucleus of a particular cell.  The 
model presented in this dissertation thus makes a significant and unique contribution to 
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